

## INDEX

Note: Page numbers in *italics* indicate figures. Page numbers followed by a “t” indicate tables.

- ACAM2000, 124t, 479, 482t, 483-484. See also *Smallpox*.
- Acetaminophen, 145
- ACIP. See *Advisory Committee on Immunization Practices*.
- ActHIB (Hib-T), 121t, 173t, 191, 344, 345, 346t-347t
- Active Bacterial Core surveillance (ABCs), 76
- Acute disseminated encephalomyelitis (ADEM), 269-270
- Ad-hoc committees and task forces, 81
- Adacel (Tdap), 65t, 123t, 205, 330t-332t. See also *Tdap vaccines*.
- Adaptive immune system, 19, 24, 25, 27
- Additives in vaccines, 259, 537
- Adenovirus, 303-308
  - clinical features, 303-304
  - epidemiology and transmission, 304
  - immunization program, 304
  - pathogen, 303
  - vaccine, 16, 304, 305t
    - contraindications/precautions, 306-307
    - immunogenicity/efficacy, 306
    - recommendations, 305t, 307
    - safety, 306-307
    - storage, 120t
- Adjuvants, 26, 27, 28t-29t, 258, 537. See also *specific vaccines*.
- action mechanisms of, 28t-29t
  - alum/aluminum, 26, 28t, 258
  - antigen sparing and, 26
  - AS01, 29t, 258
  - AS03, 28t, 401
  - AS04, 28t, 258
  - CpG 1018, 29t, 258, 364t
  - MF59, 29t, 258
  - thimerosal, 254, 264-266
- Administration of vaccines, 118-119, 135-181. See also *Delivery of vaccines; Recommendations; Vaccine practice*.
- anxiety, pain, and fever, dealing with, 142-145
  - coding and billing for, 146-150, 148t-149t
  - contraindications and precautions, 177-178
  - emergencies following, 145-146
  - errors in administration, 167, 171t
    - corrections for, 172t-176t
    - expired or invalid doses, 118, 155, 167, 172t
  - general issues, 135-137
    - air bubbles, 135-136
    - quick jab technique, 137, 144
    - general recommendations, 153-181
    - gloves not required for, 110, 135
- Administration of vaccines, *continued*
- grace period, 111-112, 154, 155, 163
  - interchangeability of vaccines from different manufacturers, 164
  - intervals for vaccinations, 153-167, 156t-162t
    - doses in a series, 163-164
    - doses of same vaccine, 155-163
    - inactivated vaccines, 154-155
    - lapse in series and, 163-164
    - between live vaccines and antibody-containing blood products, 165-166, 168t-170t
    - live vaccines not given at the same time, 154
    - simultaneous administration, 64t, 153-154
    - minimum age and intervals, 154-167, 156t-162t, 290
  - multiple vaccines
    - simultaneous administration of, 64t, 94, 137, 153-154
    - exceptions, 153
      - no maximum number of vaccinations in single day, 177
      - using different sites for, 137, 153
  - needle type and length, 142, 143t
    - for persons who have had the disease, 165, 181t
  - prefilled syringes, 119, 177
  - routes of administration, 137-142
    - errors in, 167
    - intradermal, 141, 142
    - intramuscular, 137-142, 141
    - intranasal, 142, 144
    - jet injectors, 142
    - needle type and length, 142, 143t
    - oral, 142, 144
    - subcutaneous, 141, 142
  - schedules for. See *Schedules*.
  - ten simple rules, 153-167
    - waiting (observation) time after, 145
    - “when in doubt, vaccinate,” 165
- Adolescent immunization, 95, 134, 287-288
- barriers to immunization, 92-93, 96t
  - coverage goals, 91
  - coverage rates, 73, 74
  - Denver Health example, 134, 135t
  - DTap series vs Tdap, 326-328, 337-338
  - hepatitis B vaccine, 290, 369-370
  - HPV vaccine, 290, 294, 298, 380, 383t, 385-386
  - immunization platforms
    - early adolescent, 287, 302t
    - late adolescent, 287-288, 302t
  - improving delivery, 134, 135t
  - N meningitidis*, 95, 290, 432, 433, 434, 442-443
  - schedules, 442-443
    - catch-up, 294-295
    - routine (for healthy persons), 290-291

- Adolescent immunization, *continued*  
 routine young adult, 298-299  
 special immunizations, 296t-297t  
 standards for, 92-95  
 syncope and, 145  
 tactics for vaccine delivery, 135t
- Adoptees, international, 220-221, 350
- Adult immunization, 287, 298-300. See also *Older adults*.  
 coverage goals, 91-92  
 improving rates of, 134, 136t-137t  
 at pediatric office visit, 130, 131t  
 schedules. See also *specific vaccines*.  
 by age group, 298-299  
 by medical indication, 300-301  
 standards for, 95-97, 98t-99t  
 young adult immunization platform, 302t
- Adventitious agents, 273
- Adverse events, 76-81. See also *Vaccine Safety Net; specific vaccines*.  
 causality and, 77, 77t, 97, 236  
 clinical trials and numbers of subjects to detect, 56-58, 57t  
 clustered anxiety-related adverse events, 278  
 contraindications and precautions, 177-178  
 screening for, 134, 138t-140t, 240t-241t  
 definition of, 77, 77t  
 effect on recommendations, 238t  
 genetics and, 43-46  
 mandatory reporting requirements, 77, 94, 101  
 Reportable Events, 97-101, 106t-109t  
 Reporting System (VAERS), 77-79, 101
- Advisory Committee on Immunization Practices (ACIP), vi, 63-70, 66  
 recommendations, vi-vii, 63-70, 64t-65t, 539  
 Category A or B, 70, 72t  
 GRADE approach, 67-70, 71t  
 for pregnancy and breast-feeding, 211  
 on simultaneous administration of vaccines, 64t, 154  
 working groups of, 67
- Advocacy organizations, 555t-556t
- Affinity maturation, 25, 26
- Affordable Care Act (ACA), 82
- AFIX, 134
- Afluria (IIV, influenza), 144, 398t
- Age. See also *Schedules for immunization*.  
 definition of, vii  
 grace period and, 111-112, 154, 155, 163  
 minimum ages for vaccines, 19, 154-167, 156t-162t, 290
- Agencies and committees, 54, 66
- AIDS. See also *HIV*.  
 polio vaccine not the cause of, 271  
 response to vaccines and, 185
- Alcoholism, vaccinations recommended, 300-301
- Allergies, 177, 260-262. See also *specific vaccines*.  
 allergic reactions to vaccine components, 177, 259, 333, 336.  
 See also *Contraindications and precautions*.  
 to eggs, 259, 523  
 hygiene hypothesis and, 260
- Allied Vaccine Group, 555t
- Alternative schedules, 248, 259-260
- Alum/aluminum salts, 26, 28t, 258
- American Academy of Family Physicians (AAFP), vii, 287, 539, 554t
- American Academy of Pediatrics (AAP), vii, 133, 554t  
 recommendations, 70-71, 287, 539  
 Red Book, 71
- American College Health Association (ACHA), 554t
- American College of Nurse-Midwives, 287
- American College of Obstetricians and Gynecologists (ACOG),  
 287, 554t
- American College of Physicians (ACP), 95, 287, 554t
- American Immunization Registry Association, 555t
- American Medical Association (AMA), 555t
- American Nurses Association (ANA), 555t
- American Pharmacists Association (APA), 555t
- American Public Health Association (APHA), 555t
- Anamnestic response, 22, 26, 31
- Anaphylaxis, 106t-107t, 146, 369  
 signs and symptoms of, 146
- Animal workers, vaccination of, 111, 228t, 460t
- Anogenital warts, 378, 379, 384, 568t
- Anthrax, 309-316  
 antibiotic therapy, 310, 311  
 bioterrorism potential, 309-310  
 clinical features, 309  
 epidemiology and transmission, 309-310  
 immunization program, 310  
 monoclonal antibodies, 311  
 pathogen, 309, 568t  
 vaccine, 12t, 311, 312t  
 characteristics and specifics of, 312t  
 contraindications/precautions, 313  
 immunogenicity/efficacy, 311  
 recommendations/schedule, 313  
 bioterrorism recommendations, 310  
 civilian use, 310, 314t-315t  
 military use, 311, 313  
 postexposure prophylaxis, 311, 312t  
 pre-exposure vaccination, 310-311, 312t  
 safety, 311-312  
 storage, 120t

- Antibodies, 19-21, 27. See also *Immune globulin; Immune response*.  
 action mechanisms and sites, 19-21, 20  
 antibody-dependent cell-mediated cytotoxicity, 19-21, 35  
 broadly neutralizing, 21  
 engineered, 19  
 germline, 23  
 high-affinity, 25, 27  
 passive immunization with, 11, 18-19  
 persistence of, 27-31  
 prevention of viral infection, 21  
 production of, 21-32, 22  
   adjuvants and, 26, 27, 28t-29t, 258  
   extrafollicular reaction, 21-23, 22  
   germinal center reaction, 22, 23-32  
   priming and boosting, 26-27, 30, 31  
   quantification/measurement of, 40  
 specificity of, 19, 27, 27  
 testing for, 167-171  
   rubella antibodies, 210  
 time course of responses, 26-27, 30  
 to toxins, 40  
 Antibody-containing products, intervals for live vaccines and, 165-166, 168t-170t  
 Antigen-presenting cells (APCs), 22, 24-25, 31-32, 34  
 Antigens, 11, 20, 27. See also *Antibodies*.  
 adjuvants and, 26, 27  
 antigen sparing, 26  
 antigenic competition, 537  
 antigenic drift, 391  
 antigenic shift, 391  
 cross-reactive, 27  
 immunogenicity, 31-32  
 number of  
   in combination vaccines, 539  
   in routine vaccines, 256, 257t  
 polysaccharide, 17, 21-23, 22, 31  
 reassortment, 16, 391, 401  
 T-cell independent, 23  
 Antitoxins, 19  
 Antivaccinationism, 248-249, 250t-252t  
 Anxiety, dealing with, 142-145  
 APCs. See *Antigen-presenting cells*.  
 Apoptosis, 32  
 Apremilast, 201  
 AS01, 29t, 258  
 AS03, 28t, 401  
 AS04, 28t, 258  
 Aspirin, Reye syndrome and, 138t, 228t, 406, 408, 513  
 Asplenia, 194, 199-200, 296t, 300-301, 345, 348  
 Association for Prevention Teaching and Research, 555t  
 Association of State and Territorial Health Officials, 555t  
 Asthma, 200, 261, 407  
 Attenuation of vaccines, 11-16, 12t  
   altered site of infection, 16  
   engineered, 16  
   heterologous host, 16  
   reassortment, 16  
   serial passage, 11-16  
 Autism, 263-266  
   MMR vaccine and, 263-264  
   Omnibus Autism Proceedings, 265-266  
   thimerosol and, 264-266  
 Autoimmunity, 25, 260-262  
   autoimmune diseases, 200, 260-262  
 B cells, 21-23, 25, 27  
   activation of, 21, 25  
     bystander activation, 30  
   B-cell deficiencies, 191-198  
   B-cell receptor, 21, 22, 31  
   clonal expansion/proliferation of, 21, 25  
   differentiation of, 27-30  
   memory B-cells, 22, 25-26, 27, 31  
 Bacille Calmette-Guérin (BCG), 16  
*Bacillus anthracis*, 309, 568t. See also *Anthrax*.  
 Bacteria. See also *specific bacteria*.  
   Active Bacterial Core surveillance system, 76  
   antibody effects on, 19-21, 20  
   attenuation of, 16  
   Tc-cells and, 32-35  
   vaccines against, 35  
 BARDA (Biomedical Advanced Research and Development Authority), 62  
 Barrier defect, 188-189  
 BCG (Bacille Calmette-Guérin), 16  
 Behavioral Risk Factor Surveillance System (BRFSS), 73-75, 557t  
 Bell's Palsy, 276, 442  
 Bexsero. See *MenB-4C*.  
 Bill & Melinda Gates Foundation, 555t  
 Biologics License Application (BLA), 54, 58-59  
 Biomedical Advanced Research and Development Authority (BARDA), 62  
 Bioterrorism  
   anthrax and, 309-310  
   smallpox and, 46-47, 478  
 BioThrax, 120t, 312t. See also *Anthrax*.  
 Bird flu (influenza A; H5N1). See also *Influenza*.  
 Birth defects, 177, 205, 277-278  
   percentage of all babies born with, 210  
   varicella and, 508

- Birth vaccinations, 211, 290, 362, 368, 369  
 BLA (Biologics License Application), 54, 58-59  
 Bleeding diathesis, 228t  
 Blood transfusion, interval for live vaccines and, 169t  
 Bloodborne Pathogens Standard, 105-111  
 Bone marrow (HSCT) transplantation, 204, 206t-209t  
 Books on vaccines, 558t  
 Booster vaccination, 26-27, 30, 31  
 Boostrix (Tdap), 65t, 123t, 205, 329, 330t-332t, 338.  
   See also *Tdap vaccines*.  
*Bordetella pertussis*, 17, 323, 325, 568t. See also *Pertussis*.  
 Botulism, immune globulin (BabyBig), 169t  
 Brain damage, pertussis vaccine concerns, 266-267  
 “Breakthrough therapy” category, 59  
 Breast-feeding, 180t, 211, 475, 486t, 524. See also *Pregnancy*.  
 BRFSS (Behavioral Risk Factor Surveillance System), 73-75, 557t  
 Brighton Collaboration, 80, 555t  
 Butte County, California (hepatitis A in), 43, 351
- Cancer, 377-378, 379, 379  
   anal, 379, 379  
   cervical, 377-378, 379  
   chemotherapy for, 203-204, 348  
   hepatocellular, 362  
   HPV and, 255-256, 377-379, 379  
   oral, 378, 379  
   penile, 378, 379  
   polio vaccine and, 270-271  
   vaginal, 378, 379
- Catch-up immunization schedules  
   children, age 4 months-6 years, 292-293  
   children, age 7-18 years, 294-295
- Causal relationships, 77t, 99, 233-236, 236
- CBER, 53-55, 54, 66
- CD4, 22, 24, 32, 34, 184
- CD8, 32, 34, 184
- CD40, 22, 198
- CDC. See *Centers for Disease Control and Prevention*.
- Celiac disease, 262
- Centers for Biologics Evaluation and Research (CBER), 53-55, 54, 66
- Centers for Disease Control and Prevention (CDC), 62, 66, 554t  
   disease surveillance, 76  
   vaccine stockpiles, 87, 401
- Cerebrospinal fluid. See *CSF leaks*.
- Cervarix (HPV2), 380. See also *Human papillomavirus*.
- Cervical cancer, 256, 377-378, 379  
   CIN grades, 377-378
- Chemotherapy, 203-204, 348
- Chickenpox, 35, 164, 255, 480t, 507, 508. See also *Varicella*.  
   acyclovir used to prevent, 516  
   differentiating from smallpox, 480t-481t  
   as nearly eliminated in the US, 511  
   potentially caused by lesions from herpes zoster, 528  
   questionable history of, 165
- Children. See also *Adolescent immunization*; *Infants*.  
   aspirin therapy and, 408  
   Childhood Immunization Support Program, 71  
   cocooning strategy, 130, 326-328  
   coding for routine visit, 147, 148t-149t  
   costs of immunization, 82t  
   coverage goals, 91  
   coverage rates, 73, 74  
   HIV-infected, 187-191  
   immunization schedules, 290-295  
     catch-up, age 4 months-6 years, 292-293  
     catch-up, age 7-18 years, 294-295  
     exemptions from, 112-113  
     financing for, 82-83  
     grace period, 111-112, 154, 155, 163  
     routine immunizations, age 0-18 years, 290-291  
     special immunizations, 296t-297t  
   immunization standards, 92-95  
   impact of routine childhood vaccination, 52t  
   National Childhood Vaccine Injury Act, 77, 81, 97-101  
   pain relief for, 142-145  
   participation in Immunization Information Systems (IISs), 133  
   school-aged immunization platform, 302t  
   school-located vaccination (SLV), 131-132  
   specific vaccines  
     hepatitis A, 290, 351  
     hepatitis B, 290, 362-363, 369-370  
     HPV, 380, 385-386  
     influenza, 394, 396, 407-408  
     MMR, 428  
     MMRV, 539  
     pneumonia, 495-496  
     polio, 449  
     Tdap and DTaP, 290, 327, 337  
     varicella, 509, 514  
   Vaccines for Children (VFC) Program, 63, 82-83, 84t-85t
- Children’s Health Insurance Program (CHIP), 86
- Children’s Hospital of Philadelphia Vaccine Education Center, 555t
- Children’s Vaccine Program at PATH, 555t
- Cholera, 317-322  
   clinical features, 317  
   epidemiology and transmission, 317-318  
   immunization program, 318  
   pathogen, 317, 568t

- Cholera, *continued*  
 vaccine, 319, 320t-321t  
 contraindications/precautions, 319-321  
 immunogenicity/efficacy, 319  
 recommendations, 320t, 321  
   for travel, 227, 321  
 safety, 319-321  
 storage, 123t  
 trade name (Vaxchora), 319, 320t
- Cholera toxin, 317, 318
- Chronic fatigue, 278
- Chronic granulomatous disease (CGD), 184
- Classification of vaccines, 12t-13t
- Clinical Immunization Safety Assessment (CISA) Network, 79-80, 555t
- Clinical trials, 55-58, 56  
 for combination vaccines, 537-538  
 human subjects, protection of, 55  
 numbers of subjects required, 56-58, 56, 57t  
 phase 1, 2, 3, and 4 trials, 55-58, 56
- Clonal expansion/proliferation, 21, 25
- Clostridium tetani*, 323, 325, 568t. See also *Tetanus*.
- Clotting-factor disorders, 297, 356
- CoCASA, 134, 557t
- Cochlear implants, 186, 406
- Cocooning strategy, 130, 326-328
- Coding and billing, 146-150, 148t-149t  
 CPT codes, 146-147, 148t-149t  
 ICD codes, 147, 148t-149t  
 NDCs (National Drug Codes), 147  
 reimbursement according to antigens delivered, 538  
 routine infant office visit (example), 147, 148t-149t
- College students, vaccination of, 228t, 433, 434, 443
- Combination vaccines, 537-552, 569t  
 adjuvants and excipients in, 537, 543t, 549t  
 advantages of, 537-538  
   improved coverage and timeliness, 538  
   reduction in number of shots, 153, 537, 538  
 clinical trials for, 537-538  
 contraindications/precautions, 539  
 immunogenicity/efficacy, 538  
 noninferiority standard, 538  
 overimmunization, concern about, 539  
 preference for, 539  
 production and usage issues, 437  
 recommendations, 539  
 reimbursement for, 538  
 safety, 538-539  
 specific vaccines, 540t-551t, 569t  
   DTaP-based, 120t, 538-539, 540t-546t
- Combination vaccines, *continued*  
 other than DTaP-based, 548t-551t  
 terminology and nomenclature, vii, 568t-569t
- Common variable immunodeficiency (CVID), 184-185, 191
- Communicating about vaccines, 233-244. See also *Concerns about vaccines, addressing*.  
 antivaccinationism, 248-249, 250t-252t  
   public harm from, 249-254  
 biases, 233-236  
 causality, ideas about, 233-236, 236  
 HPV vaccine for adolescents, 386-388, 387t  
 human nature and perceptions, 233-237, 236  
 pitfalls to avoid, 245t  
 questionnaires, 240t-241t, 243  
 risks vs benefits, 233-244  
 sources of information, 240-241, 242  
 specific concerns, 254-279  
 strategies for, 237-244, 240t-241t, 387t  
 vaccine confidence, teaching, 244  
 vaccine refusal, 246-248, 246
- Community education, 134
- Community immunity. See *Herd immunity*.
- Community service providers, 229t
- Compensation. See *Vaccine Injury Compensation Program*.
- Complement deficiencies, 184, 194-195, 199, 300-301, 345
- Complement-mediated lysis, 19, 20
- Component vaccines, 12t, 17-18
- Comprehensive Clinic Assessment Software Application (CoCASA), 134, 557t
- Concerns about vaccines, addressing, 233-285  
 action vs inaction, 233  
 antivaccinationism, 248-249, 250t-252t  
   emotional appeals and tropes, 249, 250t, 251t  
   flawed thinking, 252t  
   public harm from, 249-254  
 causal relationships, 233-236, 236  
 communicating risks and benefits, 233-244  
   biases, 233-236  
   communication strategies, 237-244, 240t-241t, 387t  
   human nature and, 233-237, 236  
   language and meaning, 245t  
   questionnaires, 240t-241t, 243  
   risk vs benefit, balancing, 237, 238t  
   safety, meaning of, 237  
   sources of information, 240-241, 242  
 costs of public concern, 249-254  
 risks vs benefits, balancing, 237, 238t  
 sources of information on vaccines, 240-241, 242  
 specific concerns, 254-279  
 additives, 259

- Concerns about vaccines, addressing, *continued*
- adjuvants, 258
  - adventitious agents, 273
  - AIDS, polio vaccine and, 271
  - allergies and autoimmune diseases, 260-262
  - alternative schedules, 259-260
  - autism, 263-266
  - Bell's Palsy, 276
  - brain damage, pertussis vaccine and, 266-267
  - cancer, SV40 contamination and, 270-271
  - chronic fatigue, 278
  - clustered anxiety-related adverse events, 278
  - demyelinating diseases, 268-270
  - febrile seizures, 274
  - fetal tissue, 263
  - Guillain-Barré syndrome, 267-268
  - immune overload, 256-258
  - immune thrombocytopenia, 237, 275
  - Kawasaki disease, 272-273
  - mad cow disease, 270
  - miscarriage and birth defects, 277-278
  - multiple sclerosis, 268-269
  - narcolepsy, 276-277
  - natural vs vaccine-induced immunity, 255-256
  - necessity of vaccines, 254-255
  - nonspecific negative effects, 262-263
  - polio vaccine, AIDS pandemic and, 271
  - primary ovarian insufficiency (POI), 278-279
  - rotavirus vaccines and intussusception, 237, 274-275
  - SIDS, 271-272
  - thimerosal, 264-266
  - vaccine acceptance, hesitancy, and confidence, 233, 234t, 244
  - vaccine refusal, 246-248
- Confirmation bias, 233-236
- Conjugate (protein-polysaccharide) vaccines, 31-32, 33t
- Contaminants, 177, 259, 270-271, 273, 537. See also *specific vaccines*.
- Contraindications and precautions, 177-178. See also *specific vaccines*.
- definitions, 177, 178
  - distinguishing between, 178
  - illness as, 178, 180t
  - misconceptions and erroneous contraindications, 129, 178, 180t-181t
  - screening for, 134, 138t-140t, 240t-241t
- Correctional facility staff/inmates, 229t, 356, 362, 370, 371
- Correlates of protection, 36-40, 38t-39t
- problems with, 37-40
  - uses of, 36-37
- Corynebacterium diphtheriae*, 323, 325, 568t. See also *Diphtheria*.
- Costs, 82-86, 150. See also *Financing of immunization*.
- public sector funds, 82-86
- Costs, *continued*
- of routine childhood vaccinations, 52t, 82t
  - savings due to immunization, 52t
  - of vaccine administration, 147
  - of vaccine development, 53
  - of vaccine-preventable diseases, 95
  - vaccine purchasing group, 147
  - of vaccines, 82t, 147, 150. See also *specific vaccines*.
    - purchase price, 82t, 150
    - variation in, 150
- Coverage, 73-75, 557t
- defined, 73
  - goals, 91-92
    - for adolescents, 91
    - for adults, 91-92
    - for children, 91
  - improved, with combination vaccines, 538
  - monitoring, 73-75
  - rates for adolescents, 73, 74
  - rates for children, 73, 74, 75
  - school surveys, 75
  - in special populations, 186-187, 192t-193t
- Cows, mad cow disease, 270
- CpG 1018, 29t, 258, 364t
- CPT codes, 146-147, 148t-149t
- Cross-presentation, 35
- Cross-protection, 27, 36
- CSF leaks, 186, 296t, 406
- Cultural cognition, 243
- Current Procedural Terminology codes. See *CPT codes*.
- Cytokines, 22, 24, 34
- Cytotoxic T cells (Tc cells), 25, 32-36, 34
- activation of, 32, 34
  - cross-protection and, 36
  - implications for vaccination, 32-35
- Cytotoxicity, antibody-dependent cell-mediated, 19-21
- Daptacel (DTaP), 120t, 330t-332t. See also *DTaP vaccines*.
- Day care centers
- immunization mandates for, 111-113
  - vaccination of workers, 229t, 356
- Deaths
- from influenza, 392, 393-394, 394
  - from measles, 418
  - from pneumonia, 216, 490
  - premature, 262-263
  - from smallpox, 46, 477
  - sudden infant death syndrome (SIDS), 271-272
  - from vaccine-preventable diseases, 95, 392, 393-394, 394

- Defense Medical Surveillance System (DMSS), 80
- Deferral of doses, 87
- Delayed-type hypersensitivity, 177
- Delivery of vaccines, 128-134
  - documentation of vaccinations received, 128
  - immunization coalitions, 134
  - Immunization Information Systems (IISs), 132-133
  - medical home and immunization neighborhood, 129-130
  - missed opportunities, 129, 178
  - monitoring, 73-75
  - other strategies for improving, 134
    - AFIX, 134
    - community education, 134
    - 4 Pillars Program, 134, 136t-137t
  - reminder, recall, and tracking systems, 128-129
  - school-located vaccination, 131-132
  - standing orders, 132
- Demyelinating diseases, 267-270
- Dendritic cells, 23-24
- Denver Health, adolescent immunization strategies, 134, 135t
- Department of Defense (DOD), 66
  - Defense Medical Surveillance System, 80
- Development of vaccines. See *Vaccine development and licensure*.
- Developmentally disabled, staff of institutions, 229t, 370, 371
- Diabetes, 261-262
  - vaccination recommendations, 186, 297t, 300-301, 370
- DiGeorge syndrome, 178, 184, 198
- Diphtheria, tetanus, and pertussis, 323-341. See also *individual entries for Diphtheria, Tetanus, Pertussis*.
  - clinical features, 324-325
  - epidemiology and transmission, 325-326
  - immunization programs, 326-328
  - pathogens, 323-324, 568t
  - vaccines, 328, 330t-332t, 334t-335t
    - administration errors and remedies, 172t-173t
    - characteristics and specifics of, 330t-332t, 334t-335t, 568t
    - combination vaccines, 540t-546t
    - contraindications/precautions, 333-337
    - DTaP-based, 330t-332t, 540t-546t
    - immunogenicity/efficacy, 328-333
    - recommendations, 326-328, 327, 337-338
      - adolescents, 326
      - adult. See *Tdap vaccines*.
      - children/infants. See *DTaP vaccines*.
    - safety, 333-337
    - trade names, 330t
      - Adacel (Tdap), 330t-332t
      - Boostrix (Tdap), 330t-332t
      - Daptacel (DTaP), 330t-332t
- Diphtheria, tetanus, and pertussis, *continued*
  - Infanrix (DTaP), 330t-332t
  - waning immunity, 329
- Diphtheria, 323-341. See also *Pertussis; Tetanus*.
  - clinical features, 324
  - correlates of protection, 38t
  - epidemiology and transmission, 325
  - immunization program, 326
  - pathogen, 323, 325, 568t
  - resurgence of, 326
  - vaccines, 12t, 328, 330t-332t, 334t-335t, 568t. See also *DT; DTaP vaccines; Tdap vaccines*.
    - combination vaccines, 538-539, 540t-546t
    - contraindications/precautions, 333-337
    - DTwP replacement by DTaP, 255, 326, 537
    - immunogenicity/efficacy, 328-333
    - recommendations, 326-328, 327, 337-338
    - safety, 333-337
    - schedule, 331t, 334t, 337-338
    - storage, 120t
    - trade names, 330t, 334t
      - Adacel (Tdap), 330t-332t
      - Boostrix (Tdap), 330t-332t
      - Daptacel (DTaP), 330t-332t
      - Diphtheria and Tetanus Toxoids Adsorbed (DT), 334t-335t
      - Infanrix (DTaP), 330t-332t
      - Tenivac (Td), 334t-335t
    - waning immunity, 329
- Diphtheria and Tetanus Toxoids Adsorbed (DT), 120t, 334t-335t
  - contraindication and precautions, 336-337
- Disease-modifying antirheumatic drugs (DMARDs), 200-201
- Documentation of vaccinations received, 128
- Dosing
  - administration errors, and remedies, 167, 171t-176t
  - correction for errors in, 172t
  - deferral of doses, 87
  - expired or invalid dose, 118, 155, 167, 172t
    - partial or fractional doses, 172t, 177
- Drug users, injecting, 228t, 297t, 355, 370, 371
- DT (diphtheria, tetanus toxoids), 120t, 334t-335t, 337
  - contraindications/precautions, 336-337
- DTaP vaccines, 330t-332t, 540t-546t. See also *Diphtheria, tetanus, and pertussis*.
  - administration errors and remedies, 172t-173t
  - combination vaccines, 120t, 538-539, 540t-546t
    - Kinrix (DTaP-IPV), 120t, 540t-546t
    - Pediarix (DTaP-HepB-IPV), 64t, 540t-546t
    - Pentacel (DTaP-IPV/Hib-T), 120t, 449, 540t-546t
    - Quadracel (DTaP-IPV), 120t, 540t-546t
    - Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t

- DTaP vaccines, *continued*  
 contraindications/precautions, 333-336  
 DTwP replaced by, 255, 326, 537  
 immunogenicity/efficacy, waning immunity and, 329  
 minimum ages and intervals, 155-162, 156t, 290  
 recommendations, 327, 331t, 337  
   preference for same product for entire series, 164  
   wound management, 340t-341t  
 safety, 333-336  
   encephalopathy and, 177, 269, 333  
 schedule, 331t, 337  
   children, age 0-18 years, 290  
   catch-up, children age 4 months-6 years, 292  
 storage, 120t  
 trade names (Daptacel, Infanrix), 330t-332t  
 vs Tdap, 164  
 waning immunity and, 329  
 DTwP vaccine, 255, 262, 266, 326, 547
- Eculizumab (Solaris), 199  
 Education on immunizations, 93  
 Effectiveness of vaccines, vs efficacy, 36, 58  
 Efficacy. See also *specific vaccines*.  
   correlates of protection, 36-40, 38t-39t  
   effectiveness vs, 36, 58
- Eggs  
 allergy to, 259, 523  
 influenza vaccines, “egg-free,” 398t, 401  
 serial passage in, 11
- Elimination of disease, 46-48, 49t
- Emergencies, 127t, 145-146  
 anaphylaxis, 146  
 power and weather, vaccine storage during, 127t  
 PREP Act, 101, 484  
 syncope, 106t-109t, 145-146
- Emergency preparedness, 62, 101, 145-146  
 for anaphylactic reactions, 146  
 Public Readiness and Emergency Preparedness (PREP) Act, 101, 484  
 vaccine stockpiles for, 62, 87, 401, 483  
 vaccine storage and handling, 127t
- EMLA cream, 145
- Encephalitis  
 Japanese encephalitis, 411-416  
 measles and, 418  
 postvaccination (vaccine-associated neurotropic disease), 523, 525  
 smallpox and, 477  
 varicella and, 508  
 yellow fever vaccine and, 523
- Encephalopathy, 106t, 269-270  
   acute, as vaccine contraindication, 177  
   DTaP/Tdap vaccine and, 177, 266, 333, 336  
 Engerix-B (Hep-B vaccine), 121t, 363, 364t-367t, 370  
 Engineered agent vaccines, 12t, 17-18  
 Engineered antibodies, 19  
 Engineered subunits, 12t, 17-18  
*Epidemiology and Prevention of Vaccine-Preventable Diseases*.  
   See “*Pink Book*”.
- Epitopes, 19, 27  
   carrier-induced epitopic suppression, 537  
   epitope spread, 26
- Eradication of disease, 46-47, 49t
- Errors in administration of vaccines, 167, 171t  
   corrections for, 172t-176t
- ESRD, vaccinations in, 300-301, 370
- Excipients and contaminants, 177, 259, 537. See also *specific vaccines*.
- Exemptions from immunization requirements, 112-113
- Extinction of disease, 46-47
- Extrafollicular reaction, 21-23, 22
- Families Fighting Flu, 555t
- FDA. See *Food and Drug Administration (FDA)*.
- Fear of vaccines, harm from, 249-254
- Febrile multiple organ-system failure, 521-523
- Febrile seizures, 145, 154, 274, 411, 420, 424, 538-539
- Fetal tissue in vaccine manufacture, 263
- Filamentous hemagglutinin (FHA), 17, 323, 330t
- Fimbriae (FIM), 17, 323, 330t
- Financing of immunization, 81-86  
   public sector funds, 82-86  
   Section 317 funds, 83-86  
   state and local funds, 86  
   universal purchase states, 86  
   Vaccines for Children (VFC) Program, 82-83, 84t-85t
- Flu. See *Influenza*.
- Fluad, 398t, 401
- Fluarix (IIV, influenza), 173t, 398t
- Flublok (rIIV) (“egg-free” influenza vaccine), 398t, 401
- Flucelvax (ccIIV), 398t, 401
- Flulaval, 173t, 398t
- Flumist (LAIV, live influenza), 121t, 144, 398t
- Fluzone (IIV, influenza), 399t
- Fluzone High-Dose (hdIIV, influenza), 215, 397, 399t, 403
- Food and Drug Administration (FDA), 53, 54, 66, 554t  
   vaccine development and licensure, 53-55, 54, 78
- Food handlers, vaccination of, 228t, 356
- Foresters, vaccination of, 228t
- Formaldehyde, 17, 259
- 4 Pillars Program, 134, 136t-137t



- Freezer, storage of vaccines in, 119-126, 123t-124t
- Gardasil (HPV4), 380, 381, 384-385
- Gardasil 9 (HPV9), 121t, 380-388, 382t-383t. See also *Human papillomavirus*.
- Gastroenteritis. See *Rotavirus*.
- Gelatin, 259. See also *specific vaccines*.
- Generations United, 555t
- Genetic engineering, 12t, 16, 17-18
- Genetics of vaccine responses, 21, 43-46
  - somatic hypermutation, 25
- Genital warts, 378, 379, 384, 568t
- Germinal center reaction, 22, 23-32
  - heterotypic (cross-protective) responses, 27
  - homotypic responses, 27
  - implications for vaccination, 26-32
- Germline antibodies, 23
- Global Alliance for Vaccines and Immunization, 556t
- Gloves, 110, 135
- Good Clinical Practice (GCP), 54, 55
- Good Laboratory Practices (GLPs), 54, 55
- Good Manufacturing Practices (GMPs), 53-55, 54
- Good Pharmacovigilance Practices (GPPs), 58
- Governmental agencies and committees, 54, 66, 554t
- Grace period, 111-112, 154, 155, 163
- GRADE approach, 67-70, 71t
- Guillain-Barré syndrome, 109t, 262, 267-268, 385
  - as contraindication/precaution
    - for DTaP/Tdap vaccines, 336
    - for influenza vaccines, 267-268, 405, 407
    - for *N meningitidis* vaccines, 442
  - differentiated from rabies, 451
  - swine flu vaccine and, 80, 81
- H1N1, H3N2, H5N1. See *Influenza, strains of*.
- Haemophilus influenzae* type b (Hib), 343-348. See also *Influenza*.
  - clinical features, 343
    - societal burden from, 70
  - correlates of protection, 37, 38t
  - epidemiology and transmission, 343-344
  - immunization program, 254, 344
  - pathogen, 343, 568t
    - reservoir for, 42-43
  - vaccines, 12t, 344, 346t-347t
    - administration errors and remedies, 173t
    - characteristics and specifics of, 346t-347t
    - combination vaccines
      - Pentacel (DTaP-IPV/Hib-T), 345, 449, 538, 540t-546t
      - Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t
- Haemophilus influenzae* type b (Hib), *continued*
  - contraindications/precautions, 345
  - immunogenicity/efficacy, 344-345
  - minimum ages and intervals, 156t
  - optimizing immunity with, 191, 198, 199, 203
  - recommendations, 70, 345-348
    - for infants already infected, 165
  - safety, 345
    - reportable events, 108t
  - schedule, 345, 347t
    - adults, by age, 299
    - adults, by medical condition/indication, 301
    - children, age 0-18 years, 290
      - catch-up, children age 4 months-6 years, 292
  - storage, 121t
  - trade names, 367t
    - ActHIB (Hib-T), 344, 346t-347t
    - Hiberix (Hib-T), 344-345, 346t-347t
    - PedvaxHIB (Hib-OMP), 344, 346t-347t
- Handling, storage, and transport of vaccines, 117-128
  - administration of vaccines, 118-119
    - basics of, 117
    - during emergencies, 127t
  - Immunization Tsar/Tsarina, 117, 118t, 134
  - inventory, 117-118
    - keeping VFC vaccines separate, 118
  - signs, 117, 119, 126
  - storage of vaccines, 119-128, 120t-125t
    - correct temperature for, 119-126
  - transportation of vaccines, 126-128
- Harm. See *Public harm*.
- HAV. See *Hepatitis A*.
- Havrix (HepA), 120t, 351, 352t-354t
- HBIG. See *Hepatitis B immune globulin (HBIG)*.
- HBV. See *Hepatitis B*.
- Health care personnel, 113, 216-219
  - continuing education for, 94
  - definition of, 216
  - needlestick injuries/blood exposure, 105-111
  - postexposure evaluation and prophylaxis, 110
  - rationale for immunization, 216-217
  - reporting of adverse events, 94
  - sharps use and precautions, 105, 110
  - universal precautions, 110
  - vaccination recommendations, 94, 113-114, 217-219, 300-301
    - hepatitis A, 357
    - hepatitis B, 217-218, 362, 370
    - influenza, 113, 114, 218, 408
    - MMR, 218-219, 421
    - polio, 449

- Health care personnel, *continued*  
 smallpox, 479, 485  
 Tdap, 219, 327  
 varicella (VAR), 219, 509  
 VariZIG, 219  
 vaccine coverage rates, 192t
- Health care providers  
 addressing concerns about vaccines, 233-285  
 as trusted source of information, 240-241, 242
- Healthcare Effectiveness Data and Information Set (HEDIS), 75, 557t
- Healthy People 2020*, 91-92, 133
- Heart disease, 296t, 300-301, 486t
- Hemagglutinin, 215, 323
- Hematopoietic stem cell transplantation (HSCT), 204, 357  
 revaccination recommendations, 206t-209t, 348
- Hemodialysis, 296t, 300-301  
 Hep B, 366t, 370
- HepaGam B, 363
- Hepatitis A, 349-360  
 in Butte County, California, 43, 351  
 clinical features, 349  
 correlates of protection, 38t  
 epidemiology and transmission, 349-350  
 herd immunity and, 43, 350  
 immune globulin, 358t  
 immunization program, 48, 350-351  
 pathogen, 349, 568t  
 vaccines, 12t, 351, 352t-354t  
 administration errors and remedies, 155, 173t  
 characteristics and specifics of, 352t-354t  
 combination vaccine: Twinrix (HepA-HepB), 121t, 538, 548t-551t  
 contraindications/precautions, 355  
 immunogenicity/efficacy, 351-355  
 minimum ages and intervals, 19, 156t, 163, 290  
 recommendations, 110, 350-351, 355-357  
 for correctional facilities, 350, 356  
 for food handlers, 228t, 356  
 for morticians, 228t  
 postexposure prophylaxis, 356-357, 357, 358t-359t  
 pre-exposure prophylaxis, 224t, 355-356  
 for travel, 222-223, 350, 355  
 safety, 355  
 reportable events, 108t  
 schedule, 353t  
 adults, by age, 299  
 adults, by medical condition/indication, 301  
 children, age 0-18 years, 290  
 catch-up, children age 4 months-6 years, 293  
 catch-up, children age 7-18 years, 294  
 seroconversion rates, 351
- Hepatitis A, *continued*  
 storage, 120t  
 trade names (Havrix, Twinrix, Vaqta), 352t, 548t
- Hepatitis B, 361-376  
 clinical features, 361-362  
 correlates of protection, 37-40, 38t  
 epidemiology and transmission, 362  
 chronic carriers, 361, 362  
 HBsAg (hepatitis B surface antigen), 17, 37, 361, 363  
 HBsAg/HBsAb status and, 361-362, 374t-376t  
 testing for, 171, 187, 214, 217-218, 371-372  
 immune globulin (HBIG), 18-19, 169t, 363, 368, 372, 374t-376t  
 immunization program, 362-363  
 pathogen, 361, 568t  
 vaccines, 12t, 363, 364t-367t  
 administration errors and remedies, 173t  
 characteristics and specifics of, 364t-367t, 568t  
 combination vaccines  
 Pediarix (DTaP-HepB-IPV), 64t, 538, 540t-546t  
 Twinrix (HepA-HepB), 121t, 538, 548t-551t  
 Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t  
 contraindications and precautions, 369  
 immunogenicity/efficacy, 363-368  
 interchangeability of brands, 370  
 minimum ages and intervals, 156t, 290  
 no minimum age for, 163, 365t  
 purified subunits, 17  
 recommendations, 362-363, 369-373  
 adult vaccination, 370-371  
 for correctional facilities, 362, 370, 371  
 for diabetics, 186, 370  
 health care personnel, 217-218, 362  
 HIV-infection, 187, 370, 371  
 infants, 362, 369  
 newborns, 211, 269  
 postexposure prophylaxis, 169t, 363, 371-372, 373, 374t-376t  
 preterm/low birth weight infants, 214  
 standing orders for high-risk individuals, 370-371  
 travel, 223, 370  
 universal infant, child and adolescent immunization, 369-370  
 safety, 368-369  
 reportable events, 107t  
 schedule, 366t  
 adults, by age, 299  
 adults, by medical condition/indication, 301  
 children, age 0-18 years, 290  
 catch-up, children age 4 months-6 years, 292  
 catch-up, children age 7-18 years, 294  
 storage, 121t  
 trade names (Engerix-B, Recombivax HB, Heplisav-B), 364t

- Hepatitis B immune globulin (HBIG), 18-19, 363, 368  
 contraindications/precautions, 369  
 interval for live vaccines and, 169t  
 recommendations, 363, 372, 374t-376t  
 trade names (Nabi-HB, HepaGam B, HyperHEP B S/D), 363
- Hepatitis B surface antigen. See under Hepatitis B.
- Hepelisav-B (Hep-B vaccine), 121t, 363, 364t-367t, 368
- Herd immunity, 40-43, 41, 44
- Herd immunity threshold, 41-42, 42, 43
- Herd severity effect, 43
- Herpes zoster. See *Zoster (herpes zoster; shingles)*.
- Heterologous host, 16
- Heterologous hyperimmune sera, 19
- Heterologous infections, 256
- Heterotypic (cross-protective) responses, 27, 36
- Hib. See *Haemophilus influenzae type b*.
- Hib-OMP. See *PedvaxHIB*.
- Hib-T. See *ActHIB; Hiberix*.
- Hiberix (Hib-T), 64t, 121t, 173t, 191, 344-345, 346t-347t
- HIV (human immunodeficiency virus) infection, 187-191, 271  
 adults, 191  
 children/adolescents, 187-191  
 infants, 187  
 postexposure prophylaxis, 110  
 vaccination recommendations, 187-191, 296t, 300-301  
   for close contacts, 185  
   contraindications/precautions, 187, 191  
   *H influenzae type b* (Hib), 191  
   hepatitis B, 187, 191, 370, 371  
   influenza, 191  
   MMR and VAR, 184, 187-191  
   *N meningitidis*, 191, 194-197, 443  
   pneumonia, 188-190, 191
- HLAs (human leukocyte antigens), 24, 45
- Homeless people, 297t, 356
- Hospital workers, 113-114
- HPV. See *Human papillomavirus (HPV)*.
- HPV2, HPV4, HPV9. See *Human papillomavirus (HPV) vaccines*.
- Human cell lines, 263
- Human immunodeficiency virus. See *HIV*.
- Human leukocyte antigens (HLAs), 24, 45
- Human nature, 233-237, 236
- Human papillomavirus (HPV), 377-389  
 cancers and, 255-256, 377-379, 379  
 clinical features, 377-378  
 epidemiology and transmission, 378-379  
 immunization program, 380  
   in Australia, 384  
 pathogen, 377, 568t  
 sexual activity and, 379
- Human papillomavirus (HPV), *continued*  
 vaccines, 381, 382t-383t  
   administration errors and remedies, 173t  
   characteristics and specifics of, 382t-383t, 568t  
   communicating about, 386-388, 387t  
   contraindications/precautions, 385  
   coverage rates in adolescents, 386-388  
 HPV2 (Cervarix), 380  
 HPV4 (Gardasil), 380, 381, 384-385  
 HPV9 (Gardasil 9), 380-388, 382t-383t  
   recommendations, 380, 382t, 385-388  
   safety, 384-385  
   schedule, 380, 382t-383t, 386  
     adults, by medical condition/indication, 300  
     children, age 0-18 years, 290  
     catch-up, children 7-18 years, 294  
     young adult, by age group, 290, 298  
   storage, 121t  
   immunogenicity/efficacy, 381-384  
   minimum ages and intervals, 157t, 290, 382t-383t  
   recommendations, 380, 382t, 385-388  
     adolescents, 290, 294, 298, 385-386  
   safety, 262, 384-385  
     Guillain-Barré syndrome, 268, 385  
     reportable events, 109t  
     venous thromboembolic events (VTEs), 385  
   storage, 121t
- Human rabies immune globulin (HRIG), 169t, 457, 464t-465t
- Hundred-day cough, 324. See also *Pertussis*.
- Hygiene hypothesis, 260
- HyperHEP B S/D, 363
- Hyperimmune globulin, 18-19, 169t
- HyperRAB S/D (rabies immune globulin), 457
- Hypersensitivity, delayed-type, 177
- HyperTET S/D, 328
- Hyporesponsiveness, 23
- ICD codes, 147, 148t-149t
- IgA, IgG, IgM. See *Immune globulin*.
- IGIM (intramuscular immune globulin)  
 intervals for live vaccines and, 168t  
 for measles, 428
- IIV (inactivated influenza vaccine). See *Influenza, vaccines, IIV*.
- Illegal drug users, 228t, 297t, 355, 370, 371
- Illusory truth effect, 241-243
- Immigrants, 220-221  
 proof of vaccinations, 220
- Immune deficiency states, 187-204. See also *Impaired immunity; Special circumstances*.

- Immune globulin, 18-19, 168t-170t. See also *Antibodies*.  
 botulism (BabyBig), 169t  
 deficiencies, 191-198, 337, 369, 458, 513  
 hepatitis A, 168t  
 hepatitis B (HBIG), 18-19, 169t, 363, 368, 372, 374t-376t  
 IgA, 19, 21, 30, 369  
 IgG, 19, 21  
 IgM, 19, 21, 23, 30  
 impaired immunity states and, 183  
 intravenous (IGIV), 165, 168t, 185, 428  
 isotypes, 19, 21  
 for measles, 428  
 for rabies, 457  
 time course of responses, 30  
 vaccinia, 484  
 varicella (VariZIG), 18, 169t, 509, 513, 514-516
- Immune memory, 22, 25-26, 31
- Immune overload, 256-258, 537
- Immune response, 19-36  
 adaptive immune system, 19, 27  
 anamnestic response, 22, 26, 31  
 antibodies, 19-32  
   persistence of, 27-31  
 cytotoxic T cells, 32-36, 34  
 extrafollicular reaction, 21-23, 22  
 genetics and, 43-46  
 germinal center reaction, 22, 23-32  
 homotypic vs heterotypic, 27  
 innate immune system, 23-32, 27  
   stimulating, 26-27, 27, 30  
 priming and boosting, 26-27, 30, 31  
 time course of, 26-27, 30
- Immune thrombocytopenia (ITP), 237, 275, 424
- Immunity  
 correlates of protection, 36-40, 38t-39t  
 impaired. See *Impaired immunity*.  
 natural vs vaccine-induced, 255-256  
 as presumed from vaccination, 167-171  
 testing for, 167  
 waning, 48, 255, 329, 509, 527
- Immunization, 11-19  
 active, 11  
 barriers to, 92-93, 96t  
 booster, 26-27, 30, 31  
 correlates of protection, 36-40, 38t-39t  
 definition of, 11  
 ethical and moral arguments for, 111, 113, 236, 247  
 herd immunity, 40-43, 41  
 mandates and legislation regarding, 111-114  
 passive, 11, 18-19
- Immunization, *continued*  
 primary, 26-27, 30  
 reactions to. See *Adverse events*.  
 schedules. See *Schedules for immunization*.  
 standards. See *Standards, principles, and regulations*.
- Immunization Action Coalition (IAC), 556t
- Immunization Information Systems (IISs), 132-133
- Immunization platforms, 287-288, 302t
- Immunization practices, standards and guidelines for, 91-152
- Immunization programs, 46-50. See also *specific vaccines*.  
 childhood, impact of, 50, 52t  
 control/elimination/eradication/extinction of disease, 46-48, 49t  
 goals of, 46-48, 91-92  
 impact of, 48-50, 49t, 52t  
 triumphs of, 49t
- Immunization Safety Review Committee (ISRC), 81
- Immunization Tsar or Tsarina, 117, 118t, 134
- Immunocompromised states. See *Impaired immunity*.
- Immunogenicity, 31-32, 36. See also *Immune response; specific vaccines*.  
 clinical trials to determine, 56, 56  
 efficacy and, 36  
 immunogenicity bridging, 56
- Immunoglobulins. See *Immune globulin*.
- Immunology, basic, 19-36. See also *Immune response*.
- Immunosuppression. See *Impaired immunity*.
- Immunosuppressive medications, 192t, 201  
 steroids, 200
- Imogam Rabies-HT (rabies immune globulin), 457
- Imovax Rabies (RAB-HDC), 454t-456t
- Impact of vaccines, 48-50, 52t
- Impaired immunity, 183-185  
 general considerations, 183-185  
   close contacts, immunization of, 185  
   differences in immunocompromised states, 183-184  
   official recommendations vs package insert, 185  
   risks vs benefits, 183  
   suboptimal immune responses, 184-185  
 guidelines for vaccination, 183-185  
 immune deficiency states, 187-204, 296t  
   asplenia, 199-200, 296t  
   B-cell (humoral) deficiencies, 191-198  
   cancer chemotherapy, 203-204  
   complement deficiencies, 199  
   disease-modifying antirheumatic drugs (DMARDs), 200-201  
   hematopoietic stem cell transplantation, 204, 206t-209t  
   HIV infection, 187-191, 296t  
   phagocyte disorders, 183-184, 198-199  
   solid organ transplantation, 192t, 201-204, 202  
   steroids, 200  
   T-cell deficiencies, 198

- Impaired immunity, *continued*  
 live vaccine use in households of, 166-167  
 live vaccines generally contraindicated for, 178  
 newborns, 186, 211  
 optimizing immunity  
   to *H influenzae*, 191, 198, 199, 203  
   to *N meningitidis*, 191, 194-197, 199  
   to *S pneumoniae*, 186, 188-190, 191, 198, 199, 201, 203  
 other predisposing conditions, 186, 204-207  
 passive immunoprophylaxis for, 185  
 vaccine coverage rates, 192t-193t  
 vaccine recommendations, 183-204, 296t, 300-301, 345-346, 357, 358t  
   general considerations, 183-187  
   *N meningitidis*, 434  
   pneumococcal vaccines, 188-190
- Inactivated vaccines, 12t, 17-18  
 characteristics of, 14t-15t  
 component vaccines, 17-18  
 grace period and, 155  
 intervals for vaccination, 154-155  
 purified subunits, 12t, 17  
 vs live vaccines, 14t-15t, 35  
 whole agent, 12t, 17
- Inborn errors of metabolism, 214-215
- Indications, 68t-69t  
 labeled indications, 59, 64t-65t  
 vs official recommendations, 62, 64t-65t, 68t-69t
- Infanrix (DTaP), 329, 330t-332t  
 storage, 120t
- Infants. *See also Children; Newborns.*  
 birth vaccinations, 211, 290, 362, 368, 369  
 botulism immune globulin (BabyBig), 169t  
 cocooning strategy, 130, 326-328  
 hepatitis B vaccination, 211, 362, 368, 369  
   HBsAg/HBsAb testing, 372  
   post-exposure prophylaxis, 371-372  
   standing orders for, 369  
 Hib infection, 255  
   vaccinating for, 165, 345  
 HIV and, 187  
 infant-toddler immunization platform, 302t  
 maternal antibody protection, 18, 204  
 maternal immunization, benefits for, 130  
 newborns, 186, 211  
 pain relief for, 142  
 pertussis immunization, 327  
 pertussis in, 130, 205  
 preterm and low birth weight, 214, 475  
 rotavirus vaccination, 166, 469, 471t-472t, 475
- Infants, *continued*  
 routine immunization schedule, 290  
 susceptibility gap, 204  
 varicella/VariZIG, 514, 516
- Infectious Diseases Society of America (IDSA), 95, 555t
- Inflammatory reaction, 24, 258
- Influenza, 391-410  
 clinical features, 392-393  
 correlates of protection, 38t  
 deaths from, 392, 393-394, 394  
 economic burden of, 393-394, 395  
 epidemics/pandemics, 62, 391-392  
   2009 A(H1N1), 62, 267-268, 276, 392, 394  
   Spanish flu (1918), 391-392  
 epidemiology and transmission, 393-394  
   annual mortality, 393-394, 394  
 immunization program, 394-397, 396  
   cost-effectiveness of, 397  
   coverage goals, 92  
   school-located vaccination, 132  
 pathogen, 391-392, 568t  
   antigenic shift and drift, 391  
   reassortment and, 391, 401  
 strains, 391-392  
   A, H, and N, 391, 401  
   A(H1N1), 267, 276-277, 391-392, 397, 404  
     special surveillance efforts, 80  
   A(H3N2), 392, 397, 404  
   A(H5N1, avian flu), 391, 392, 401  
 vaccines, 397-401, 398t-400t  
   administration errors and remedies, 173t-174t  
   annual production of, 401  
   characteristics and specifics of, 398t-400t, 568t  
   “egg-free” (Flublok, Flucelvax), 398t, 401  
   IIV (inactivated), 398t-400t, 401  
     A (H5N1) vaccine, against avian flu, 401  
     administration errors and remedies, 173t  
     contraindications/precautions, 405  
     “egg-free” vaccines (Flublok, Flucelvax), 398t, 401  
     Fluad, 398t, 401  
     high-dose (Fluzone High-Dose), 215, 397, 399t, 403  
     immunogenicity/efficacy, 402-403  
     jet injector for, 142  
     safety, 404-405  
     storage, 121t  
   immunogenicity/efficacy, 402-404  
   effectiveness, 402  
   LAIV (live-attenuated), 12t, 398t, 401  
     administration errors and remedies, 174t  
     contraindications/precautions, 191, 200, 406-407

- Influenza, *continued*
- immunogenicity/efficacy, 403-404
  - intranasal administration of, 142, 144
  - reassortment backbone, 401
  - safety, 405-407
  - storage, 121t
  - quadrivalent vaccines, 397
  - recommendations, 298, 394-397, 396, 407-408
    - adults, 298, 394-397, 408
    - adults over 65 years, 215-216, 298, 396, 397, 403
    - annual vaccination, 407
    - children, 394, 396, 407-408
    - children on aspirin therapy, 408
    - during pregnancy, 210, 212t, 408
    - health care personnel, 113, 114, 218, 408
    - high risk/priority patients, 408
    - minimum ages and intervals, 157t, 290
    - for travel, 223
    - universal vaccination, 396, 408
  - safety, 404-407
    - Bell's palsy, 276
    - egg allergy and, 405
    - Guillain-Barré syndrome, 267-268, 405, 407
    - miscarriage, 278
    - MS, 268-269
    - narcolepsy, 276-277
  - schedule, 407-408
    - adults, by age, 299
    - adults, by medical condition or indication, 300
    - children, age 0-18 years, 290
  - shortages of, 86-87
  - storage of, 121t
  - trade names, 398t-400t
    - Afluria, 398t
    - Fluad, 398t, 401
    - Fluarix, 398t
    - Flublok, 398t, 401
    - Flucelvax, 398t, 401
    - Flulaval, 398t
    - Flumist, 121t, 398t
    - Fluzone, 399t
    - Fluzone High-Dose, 215, 397, 399t
- Injury. See *National Childhood Vaccine Injury Act; Vaccine Injury Compensation Program.*
- Innate immunity, 23-32, 27
  - adjuvants and, 26, 27
  - stimulating, 26-27, 27, 30
- Institute for Vaccine Safety, Johns Hopkins, 556t
- Institute of Medicine (IOM), 81
- Interferon-gamma release assay (IGRA), 484, 513, 524
- International adoptees, refugees, and immigrants, 220-221, 350
- Internet resources, 554t-557t
- Intervals for vaccinations, 153-167, 156t-162t
  - doses in a series, 163-164
  - doses of same vaccine, 155-163
  - grace period, 111-112, 154, 155
  - inactivated vaccines, 154-155
  - lapse in series and, 163-164
  - live vaccines, 154
    - between live vaccines and antibody-containing blood products, 165-166, 168t-170t
    - minimum intervals and ages, 19, 153-167, 156t-162t
    - simultaneous administration, 153-154
- Intradermal administration, 141, 142
- Intramuscular administration of vaccines, 137-142, 141
- Intravenous immune globulin (IGIV), 168t
- Intussusception, 178, 237, 274-275, 468, 474
- Inventory of vaccines, 117-118
  - keeping VFC vaccines separate, 118
  - rotation of stock, 117
- IPOL (IPV), 121t, 448t. See also *Polio, vaccines.*
- IPV. See *Polio, vaccines.*
- Isotypes, 19, 21, 23
  - isotype switching, 23, 25
- ISRC (Immunization Safety Review Committee), 81
- Ixario (JEV-VC), 121t, 413, 414t-415t
- Japanese encephalitis, 411-416
  - clinical features, 411
  - correlates of protection, 38t
  - epidemiology and transmission, 226, 412
  - immunization program, 412-413
  - pathogen, 411, 568t
  - vaccines, 12t, 413, 414t-415t
    - characteristics and specifics of, 414t-415t
    - contraindications/precautions, 415
    - immunogenicity/efficacy, 413
    - JEV-MB, 412, 413
    - JEV-VC (Ixario), 413, 414t-415t
    - recommendations, 415-416
      - laboratory workers, 416
      - for travel, 226, 415
    - safety, 413-415
    - schedule, 414t
    - storage, 121t
    - trade name: Ixario (JEV-VC), 414t
- Jenner, Edward, 16
- JEV. See *Japanese encephalitis.*

- Kawasaki disease, 168t, 272-273
- Kidney failure/disease, 186, 296t, 300-301, 470
- Kinrix (DTaP-IPV), 120t, 172t, 540t-546t
- Labeled indications, 59  
vs official recommendations, 62, 64t-65t
- Laboratory workers, vaccination of, 111, 228t, 314t, 355, 416, 443, 449, 460t, 484, 505, 524
- LAIV (live-attenuated influenza vaccine). See *Influenza, vaccines, LAIV*.
- Langerhans cells, 24
- Language and meaning, 245t
- Latex, 177. See also *specific vaccines*.
- Licensure. See *Vaccine development and licensure*.
- Life-course immunization, 215
- Live vaccines, 11-16, 12t-13t, 21  
attenuation of, 11-16  
characteristics of, 14t-15t, 21  
given enterically, 304  
grace period and, 154, 155  
intervals for receipt of antibody-containing products, 165-166, 168t-170t  
intervals for vaccinations, 154  
in pregnancy and immunocompromised persons, 14t, 166-167, 177-178, 210-211, 212t  
vs inactivated vaccines, 14t, 35
- Liver cancer, 362
- Liver disease, 186, 296t, 300-301, 356, 358t, 370
- Lockjaw. See *Tetanus*.
- Long-term care facilities, 229t
- Lung disease, vaccinations recommended, 300-301
- Lyme disease, 276  
correlates of protection, 38t
- Mad cow disease (MCD), 270
- Major histocompatibility complex (MHC), 43-45  
class I molecules (MHC-I), 32, 34, 35  
class II molecules (MHC-II), 22, 24, 25, 31, 34
- Mandates and exemptions for immunization, 111-114
- Mandatory reporting of adverse events, 77, 94, 101, 103t
- Manufacturers of vaccines, 87, 557t  
financial risk for, 53  
interchangeability of vaccines, 164  
number of, 87  
vaccine design defect claims, legal immunity from, 100-101
- Measles, Mumps, Rubella, 417-430  
clinical features, 418-419  
correlates of protection, 38t  
epidemiology and transmission, 419-420  
deaths from measles, 418
- Measles, Mumps, Rubella, *continued*  
measles endemic in UK, 221  
measles outbreaks in US, 249-254, 253  
evidence/proof of immunity, 210, 426t-427t  
immune globulin (for measles), 428  
immunization program, 420-421  
presumption of immunity with, 167-171  
pathogens, 417-418, 568t  
elimination of measles and rubella (Americas), 47, 49t, 424  
resurgence of, 48, 249-254, 420, 421-424  
measles, 249-254, 253, 421-422  
mumps, 48, 420, 423-424  
rubella  
congenital rubella syndrome (CRS), 419, 424  
declared eliminated from the Americas, 424  
proof of immunity, 210, 426t  
vaccines (MMR), 12t, 421, 422t-423t  
characteristics and specifics of, 422t-423t  
combination vaccine (MMRV), 420, 539, 548t-551t.  
See also *MMRV vaccine*.  
vs MMR plus VAR, 420, 538-539  
contraindications/precautions, 425  
evidence/proof of immunity, 210, 426t-427t  
immunogenicity/efficacy, 421-424  
interval for receipt of antibody-containing products, 165-166, 168t-170t  
recommendations, 64t-65t, 425-428  
health care personnel, 218-219, 421  
HIV-infected individuals, 187-191  
postexposure prophylaxis (measles), 428  
safety, 273, 424-425  
autism concerns, 263-264  
febrile seizures, 274, 424  
ITP, 275, 424  
reportable events, 106t-107t  
schedule, 422t-423t  
adults, by age, 298  
adults, by medical condition/indication, 300  
children, age 0-18 years, 290  
catch-up, children age 4 months-6 years, 293  
catch-up, children age 7-18 years, 294  
minimum ages and intervals, 158t, 163, 290  
storage, 122t, 124t  
trade name (M-M-R<sub>11</sub>), 422t
- Medicaid, 86, 554t
- Medical home, 129-130
- Medicare, 86, 554t
- Membrane attack complex, 19-21, 20
- Memory B-cells, 22, 25-26, 27, 31
- Memory T and Th-cells, 26, 27

- Men who have sex with men, 228t, 297t, 300-301, 355, 370
- Menactra (MenACWY-D), 40, 174t, 432, 435, 436t-439t
- immunogenicity, 440
  - minimum ages and intervals, 158t
  - recommendations, 301, 432, 434
  - safety, 268, 441-442
  - schedules, 194-195, 290, 294, 299
  - storage, 122t
- MenB, 12t, 175t, 434
- schedules, 194-195, 290, 299
  - use of same product in series, 164
- MenB-4C (Bexsero), 175t, 435, 436t-439t
- adjuvant, 28t
  - immunogenicity, 441
  - minimum ages and intervals, 157t
  - recommendations, 64t, 301, 433, 434
  - schedules, 175t, 290
  - storage, 122t
- MenB-FHbp (Trumenba), 175t, 433, 435, 436t-439t
- immunogenicity, 441
  - minimum ages and intervals, 158t
  - recommendations, 64t, 433
  - schedules, 175t
  - storage, 122t
- Meningitis, 431-432. See also *Neisseria meningitidis*.
- aseptic, 411, 419
  - bacterial, pneumonia and, 489
  - Haemophilus influenzae* type b and, 343
  - invasive meningococcal disease (IMD), 226, 432
  - meningococcal, 431-432
  - mumps and, 419
  - polio and, 445
- Meningococcal vaccines. See *Neisseria meningitidis*.
- Menveo (MenACWY-CRM), 174t, 435, 436t-439t
- Bell's palsy and, 276, 441
  - immunogenicity, 440-441
  - safety, 441
  - storage, 122t
- Mercury (thimerosal) in vaccines, 264-265
- Methotrexate, 201
- MF59 (adjuvant), 29t, 258
- MHC, MHC-I, MHC-II. See *Major histocompatibility complex*.
- Military personnel, 46, 228t, 443
- adenovirus vaccination, 307
  - anthrax vaccination, 311, 313
  - smallpox vaccination, 479, 484
- Minimum age and intervals for vaccination, 19, 153-167, 156t-162t, 290
- intervals for receipt of antibody-containing products, 165-166, 168t-170t
  - rule: all vaccines have a minimum age, 164
- Minimum age and intervals for vaccination, *continued*
- exception: no minimum age for HepB or RAB, 164
- Miscarriage, 277-278
- Missed opportunities, 129, 178
- MMR vaccine. See *Measles, Mumps, Rubella*.
- MMRV vaccine (ProQuad), 420, 539, 548t-551t. See also *Measles, Mumps, Rubella*.
- administration errors and remedies, 175t
  - contraindications and precautions, 191, 539
  - febrile seizures and, 274, 538-539
  - interval for receipt of antibody-containing products, 166, 168t-170t
  - MMR plus VAR preferred over, 420, 538, 539
  - recommendations/preference for, 539
  - storage, 124t
  - vs MMR plus VAR, 420, 538, 539
- Monitoring
- adverse events. See *Adverse events*.
  - vaccine delivery and coverage, 73-75, 128-129
  - vaccine safety, 76-81
- Monkey cells, 11
- Monocytes, 23-24
- Morbidity and mortality. See *Deaths*.
- Morbidity and Mortality Weekly Report*, 67
- Morticians, vaccination of, 228t
- MPSV4 (Menomune-A/C/Y/W-135), 433, 434, 440
- Mucosal surfaces, 21, 154, 166
- Multiple sclerosis, 268-269
- Multiple vaccines, simultaneous administration of, 64t, 94, 137, 153-154. See also *Combination vaccines*.
- exceptions, 153
  - immune overload concept, 256-258
- Mumps. See *Measles, Mumps, Rubella*.
- Mycobacterium bovis*, 16
- Nabi-HB, 363
- Narcolepsy, 276-277
- National Adult Immunization Plan, 97
- National Center for Immunization and Respiratory Diseases (NCIRD), 62, 66, 76
- National Childhood Vaccine Injury Act, 77, 81, 97-101
- National Coalition for Adult Immunization, 96
- National Drug Codes (NDCs), 147
- National Foundation for Infectious Diseases, 556t
- National Health Interview Survey (NHIS), 75, 557t
- National Immunization Survey (NIS), 73, 557t
- National Institute of Allergy and Infectious Diseases (NIAID), 554t
- National Institutes of Health (NIH), 66
- National Meningitis Association, 556t
- National Notifiable Disease Surveillance System (NNDSS), 76, 557t
- National Respiratory and Enteric Surveillance System (NREVSS), 76



- National Vaccine Advisory Committee (NVAC), 66, 71, 554t  
 adult immunization standards, 95-97, 98t-99t  
 immunization registries, 133  
 pediatric immunization standards, 92-95
- National Vaccine Error Reporting Program (VERP), 167
- National Vaccine Injury Compensation Program. *See Vaccine Injury Compensation Program (VICP).*
- National Vaccine Plan, 71
- National Vaccine Program Office (NVPO), 66, 71, 554t
- Native Americans and Alaska Natives, 229t
- Natural infection, vs immunization, 255-256
- Natural killer cells, 19-21
- Necessity of vaccines, 254-255
- Needle length, 142, 143t
- Needlestick injuries, 105
- Neighborhood, immunization, 129-130
- Neisseria meningitidis*, 431-444  
 clinical features, 431-432  
 correlates of protection, 38t  
 epidemiology and transmission, 432-433  
 serogroups, 432-433, 435, 436t  
 immunization program, 433-435, 434  
 cost-benefits, 433  
 pathogen, 431, 568t  
 vaccines, 435-440, 436t-439t  
 adjuvants, 28t  
 administration errors and remedies, 174t-175t  
 characteristics and specifics of, 436t-439t, 568t  
 combination vaccine: Vaxelis (DTaP-HepB-IPV-Hib-OMP),  
 120t, 540t-546t  
 contraindications/precautions, 153, 442  
 immunogenicity/efficacy, 440-441  
 licensure of, 40, 268  
 MenACWY, 12t, 194-195, 434  
 MenACWY-CRM, 40, 436t-439t, 440-441  
 Bell's palsy and, 276, 442  
 immunogenicity, 440-441  
 MenACWY-D, 40, 434, 436t-439t, 440  
 immunogenicity, 440  
 MenB, 12t, 194-195, 434  
 MenB-4C, 435, 436t-439t  
 MenB-FHbp, 433, 436t-439t  
 recommendations, 64t, 435  
 minimum ages and intervals, 157t-158t, 290  
 MPSV4, 433, 434, 440  
 reportable events, 109t  
 optimizing immunity with, 194-197  
 recommendations, 64t, 433-435, 434, 442-443  
 adolescents, 95, 290, 432, 433, 434  
 college students, 433, 434, 443
- MPSV4, *continued*  
 during pregnancy, 212t  
 travel, 227, 443  
 universal adolescent immunization, 432, 434, 442-443  
 use of same product in series, 164  
 safety, 441-442  
 Bell's palsy, 276, 442  
 Guillain-Barré syndrome, 268, 442  
 reportable events, 109t  
 schedule, 442-443  
 adults, by age, 299  
 adults, by medical condition/indication, 301  
 children, age 0-18 years, 290  
 catch-up, children age 7-18 years, 294  
 storage, 122t  
 trade names, 436t  
 Bexsero (MenB-4C), 436t  
 Menactra (MenACWY-D), 435, 436t  
 Menveo (MenACWY-CRM), 435, 436t  
 Trumenba (MenB-FHbp), 436t  
 Vaxelis (DTaP-HepB-IPV-Hib-OMP), 540t
- Nephrotic syndrome, 186
- Neutralization of pathogens, 19-21, 20
- New Vaccine Surveillance Network (NVSN), 76
- Newborns, 18, 186, 211. *See also Infants.*  
 Hepatitis B vaccination, 211, 214  
 maternal chickenpox, VariZIG for, 516  
 neonatal tetanus, 324, 325  
 vaccinations given at birth, 211, 290, 362, 368, 369
- Nomenclature, vi-vii, 568t-569t
- Noninferiority, 56, 538
- Nursing homes, coverage survey, 75
- Occupational Safety and Health Administration (OSHA), 105-111
- Office visit, coding and billing example, 147, 148t-149t
- Older adults, 215-216, 298-299  
 immunization platform, 302t  
 immunization schedule, 298-299  
 influenza immunization, 298, 325-326, 396, 397, 403  
 life-course immunization, 215  
 pneumonia immunization, 216, 495, 496  
 zoster vaccination, 216, 535
- Opsonization, 19-21, 20
- OPV. *See Polio, vaccines.*
- Oral administration of vaccines, 142, 144
- OSHA (Occupational Safety and Health Administration), 105-111
- Otitis media, 508
- Overimmunization, 539

- Package insert (PI), 59-62, 153-154, 185  
 labeled indications, 59, 64t-65t
- Pain (of administration), dealing with, 142-145
- Palivizumab (Synagis), 19, 166, 168t
- Pandemrix, 276-277
- Parents of Kids With Infectious Diseases, 556t
- Partial doses, 177
- Passive immunization, 11, 18-19, 185  
 during pregnancy, 18  
 potential inactivation of vaccines, 19
- Pasteur, Louis, 16, 17
- Pathogens, 568t-569t. See also *pathogen subentry under specific agents*.  
 antibody effects on, 19-21, 20  
 pathogen-specific antibodies and T-cells, 19  
 pathogen-specific molecular patterns (PAMPs), 24  
 reservoirs for, 42
- Patient Protection and Affordable Care Act (ACA), 82
- Patternicity, 236
- PCV13. See *Pneumococcal vaccines, PCV13*.
- Pediarix (DTaP-HepB-IPV), 64t, 120t, 540t-546t  
 safety, 538
- Pediatric immunization standards, 92-95. See also *Children; Infants*.
- Pediatric Infectious Diseases Society, 555t
- PedvaxHIB (Hib-OMP), 121t, 167, 191, 344, 345, 346t-347t  
 adjuvant, 28t, 258
- Pentacel (DTaP-IPV/Hib-T), 120t, 173f, 345, 449, 540t-546t
- Personal belief exemptions, 112-113
- Pertactin (PRN), 17, 323, 330t
- Pertussis, 323-341. See also *Diphtheria, tetanus, and pertussis*.  
 clinical features, 324-325  
 correlates of protection, 40  
 epidemiology and transmission, 325-326  
 prevention for infants by maternal immunization, 130  
 immunization program, 326-328, 327  
 pathogen, 323, 325, 568t  
 pertussis toxin (PT), 323-325  
 resurgence of, 48, 249  
 vaccines, 328, 330t-332t, 568t  
 combination vaccines, 538-539, 540t-546t  
 contraindications/precautions, 333-337  
 immunogenicity/efficacy, 328-333  
 recommendations, 326-328, 327, 337-338  
 adult. See *Tdap vaccines*.  
 children/infants. See *DTaP vaccines*.  
 for pregnant women, 130  
 safety, 333-337  
 allergies and, 261, 333, 336  
 brain damage concerns, 266-267  
 encephalopathy, 177, 269, 333, 336  
 reportable events, 106t
- Pertussis, *continued*  
 schedule, 331t, 337-338  
 trade names, 330t  
 Adacel (Tdap), 330t-332t  
 Boostrix (Tdap), 330t-332t  
 Daptacel (DTaP), 330t-332t  
 Infanrix (DTaP), 330t-332t  
 whole-cell, 17  
 waning immunity and, 48, 329
- Phagocyte disorders, 183-184, 198-199
- Phagocytes/phagocytosis, 19, 20, 24
- Pharmacists  
 American Pharmacists Association, 555t  
 vaccine administration by, 129-130
- Phase 1, 2, 3, and 4 trials, 55-58, 56
- "Pink Book" (*Epidemiology and Prevention of Vaccine-Preventable Diseases*), 67
- Placebo, 56
- Plasma cells, 21-23, 22, 27-30  
 longevity of, 31
- Pneumococcal vaccines, 490-496, 492t-493t  
 characteristics and specifics of, 491, 492t-493t, 569t  
 contraindications/precautions, 495  
 correlates of protection, 39t  
 immunization program, 490-491  
 cost-effectiveness of, 491  
 herd immunity and, 491  
 impact of, 43, 44, 48  
 immunogenicity/efficacy, 491-495  
 CAPITA study, 216, 494  
 minimum ages and intervals, 158t, 188-189, 290  
 optimizing immunity with, 188-190
- PCV7, 490, 491-494  
 serotype replacement and, 43, 45, 48, 490
- PCV13 (Pevnar 13), 490-491, 492t-493t, 494-496  
 administration errors and remedies, 175t  
 immunogenicity/efficacy, 494  
 minimum age and intervals, 153, 158t, 188-189, 290  
 optimizing immunity with, 188-190  
 safety, 495  
 schedule, 492t, 495-496  
 adults, by age, 299  
 adults, by medical condition/indication, 301  
 children, age 0-18 years, 290, 495-496  
 catch-up, children, age 4 months-6 years, 293  
 storage, 122t
- PPSV23 (Pneumovax 23), 491, 492t-493t, 494-496  
 administration errors and remedies, 175t  
 immunogenicity/efficacy, 216, 494-495  
 minimum age and intervals, 153, 158t, 188-189

- Pneumococcal vaccines, *continued*
- optimizing immunity with, 188-190
  - safety, 495
  - schedule, 492t
    - adults, by age, 299
    - adults, by medical condition/indication, 301
  - storage, 122t
  - recommendations, 490-491, 495-496
    - older adults, 216, 495, 496
  - replacement disease and, 490
  - safety, 495
    - reportable events, 108t
  - serotype replacement, 43, 45, 490
  - storage, 122t
- Pneumonia, 255, 489-497. See also *Pneumococcal vaccines*.
- clinical features, 489-490
    - invasive pneumococcal disease (IPD), 489-490
  - epidemiology and transmission, 490
  - immunization program, 490-491
  - impaired immunity and, 186
  - mortality from, 216, 490
  - optimizing immunity to, 188-190
  - pathogen, 489, 569t
  - serotype replacement, 43, 45, 490
- Pneumovax 23 (PPSV23), 492t-493t. See also *Pneumococcal vaccines*, PPSV23.
- Policy. See *Vaccine policy*.
- Polio, 445-450
- clinical features, 445
  - correlates of protection, 38t
  - epidemiology and transmission, 445-446
    - Americas certified free of, 47, 49t, 446, 447
    - endemic countries (in 2019), 447
    - international spread of polio, 223-226, 447
    - OPV-derived polio cases, 47, 185, 446
    - underimmunized individuals and, 446
  - immunization program, 446-447
  - pathogen, 445, 568t
  - proof of immunity, 447, 449
  - vaccines, 447, 448t
    - characteristics and specifics of, 448t
    - combination vaccines, 540t-546t
      - Kinrix (DTaP-IPV), 120t, 540t-546t
      - Pediarix (DTaP-HepB-IPV), 64t, 540t-546t
      - Pentacel (DTaP-IPV/Hib-T), 120t, 449, 540t-546t
      - Quadracel (DTaP-IPV), 540t-546t
      - Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t
    - immunogenicity/efficacy, 447
    - inactivated (IPV), 448t
      - combination vaccines, 540t-546t
- Polio, *continued*
- contraindications/precautions, 449
  - immunogenicity/efficacy, 447
  - minimum ages and intervals for, 157t, 290
  - recommendations, 449-450
  - safety, 447-449
  - schedule, 448t, 449-450
    - children, age 0-18 years, 290
    - catch-up, children 7-18 years, 294
    - catch-up, children age 4 months-6 years, 293
  - storage, 121t
  - oral (OPV), 446-447
    - 2-valent, 446, 447
    - 3-valent, 446-447, 449
    - destruction of vaccine stocks, 47
    - polio cases caused by, 47, 185, 446
    - reimmunization recommended, 449
    - proof of immunity, 447, 449
    - recommendations, 446-447, 449-450
      - for travel, 223-226, 449
    - safety, 447-449
      - AIDS not caused by, 271
      - reportable events, 107t, 109t
      - SV40 and, 270-271
      - trade name (IPOL), 121t, 448t
  - Polyclonal immune globulin, 18
  - Polysaccharide antigens, 21-23, 22, 31-32
    - immune response to, 21-23, 22
  - Polysaccharide vaccines, 17-18, 31-32, 33t
    - hyporesponsiveness and, 23
    - original polysaccharide sin, 23
    - protein-polysaccharide vaccines, 22, 31-32
      - advantages of, 31-32, 33t
    - pure, 17-18
  - Postherpetic neuralgia (PHN), 256, 527, 528
  - PPSV23. See *Pneumococcal vaccines*, PPSV23.
  - Precautions. See *Contraindications and precautions*.
  - Prefilled syringes, 119, 177
  - Pregnancy, 204-211, 212t-213t, 296t
    - hepatitis B antigen (HBsAg), testing for, 371-372
    - as indication for vaccination, 130, 177, 205, 212t, 296t
    - passive immunization in, 18, 163, 211
    - rubella, proof of immunity, 210, 426t
    - smallpox, disease effects on, 477
    - vaccination during, 204-211, 212t-213t, 296t, 300-301
      - birth defect concerns, 177, 205, 277-278
      - contraindications/precautions, 166, 177-178, 210, 212t, 296t, 425, 449, 486t, 531
      - indications for, 130, 177, 205, 212t, 296t
      - influenza, 210, 212t, 300, 406, 408

Pregnancy, *continued*

- live vaccines, 14t, 210
  - generally contraindicated during pregnancy, 177, 210, 212t
  - exceptions to, 210, 212t
  - for household contacts, 166-167, 210
- maternal immunization platform, 205, 302t
- miscarriage concerns, 277-278
- pertussis, 130
- Tdap, 205, 212t, 300, 327, 328, 338
- varicella, 210, 212t, 514
- VariZIG, 211, 514-516
- yellow fever, 177, 212t, 524, 525
- vaccine coverage rates, 192t
- PREP Act, 101, 484
- Preservatives, 259. See also *specific vaccines*.
- Prevention of infection, 19, 35
  - vs prevention of disease, 35, 76
- Pevnar, 122t, 490-491, 492t-493t. See also *Pneumococcal vaccines, PCV13*.
- Primary immunization, 26-27, 30
- Primary ovarian insufficiency (POI), 278-279
- Primary vaccine failure, 31, 60t-61t
- Priming and boosting, 26-27, 30, 31
- PRISM (Post-licensure Rapid Immunization Safety Monitoring), 79
- ProQuad, 124t, 548t-551t. See also *MMRV vaccine (ProQuad)*.
- Protein-polysaccharide vaccines, 31-32
  - advantages of, 31-32, 33t
- Public harm, from fear and refusal of vaccines, 249-254
- Public health, 46-50. See also *Concerns about vaccines, addressing*.
  - impact of vaccines, 48-50, 49t, 52t
  - risks of refusal of vaccination, 249-254
- Public health emergency
  - preparedness for, 62, 101
  - vaccine stockpiles for, 62, 87, 401, 483
- Public Readiness and Emergency Preparedness Act, 101, 484
- Public safety workers, vaccination of, 229t, 370
- Purified subunits, 12t, 17
- Purple Book*, vi

Quadracel (DTap-IPV), 120t, 172t, 540t-546t

Questions about vaccines. See *Concerns about vaccines*.

RAB-HDC (Imovax Rabies), 122t, 454t-456t, 457

RAB-PCEC (RabAvert), 122t, 454t-456t, 457

RabAvert (RAB-PCEC), 122t, 454t-456t

Rabies, 451-465

- clinical features, 451-452
- correlates of protection, 38t
- epidemiology and transmission, 226, 452
- successful treatment, 452

Rabies, *continued*

- immune globulin (HRIG), 169t, 457, 464t-465t
- immunization program, 453
- pathogen, 451, 569t
- vaccines, 12t, 453-457, 454t-456t
  - administration errors and remedies, 175t
  - characteristics and specifics of, 12t, 454t-456t, 569t
  - contraindications/precautions, 457-458
  - immunogenicity/efficacy, 457
  - no minimum age for, 163
  - postexposure prophylaxis, 65t, 453, 455t, 462t-465t
    - with immune globulin (HRIG), 169t, 457, 464t-465t
    - regimens for, 464t-465t
    - wound cleansing, 464t-465t
  - pre-exposure vaccination (prophylaxis), 453, 455t, 460t-461t
  - recommendations, 453, 458, 460t-465t
    - animal evaluation and, 462t-463t
    - for animal handlers, 111, 460t
    - for travel, 226
  - safety, 457-458
  - schedule, 455t, 460t
  - storage, 122t
  - trade names (Imovax Rabies, RabAvert), 454t
  - wildlife, oral vaccination of, 452
- Rabies immune globulin, human (HRIG), 457, 464t-465t
  - interval for live vaccines and, 169t
- Rapid cycle analysis, 79
- Reactions to vaccines. See also *Adverse events*.
  - anaphylaxis, 106t-107t, 146
  - injection-site. See *specific vaccines*.
- Reassortment, 16, 391, 401
- Recall and tracking systems, 128-129
- Recombinant DNA technology, 17-18
- Recombinant subunit vaccines, 12t, 17-18
- Recombivax HB (HepB), 121t, 363, 364t-367t, 370
- Recommendations, vii, 62-72, 153-181. See also *Administration of vaccines; specific vaccines*.
  - AAAP, 70-71
  - ACIP, vii, 63-70, 539
  - administration errors and corrections, 167, 171t-176t
  - adult immunization, 67
  - agencies involved with, 62-72, 66
  - Category A or B, 70, 72t
  - child/adolescent schedule, 67
  - considerations for making, 70
  - contraindications and precautions, 177-178
  - disease burden and, 70
  - Evidence to Recommendations (EtR) framework, 67-70
  - General Best Practice Guidelines, 67
  - general recommendations, 67, 153-181

- Recommendations, *continued*
- GRADE approach, 67-70, 71t
  - intervals for receipt of antibody-containing blood products, 165-166, 168t-170t
  - minimum age and intervals for vaccinations, 19, 153-167, 156t-162t, 290
  - official, vs labeled indications, 62, 64t-65t, 68t-69t
  - routine schedules, 287-302. See also *Schedules for immunization*.
  - special circumstances, 183-232
  - ten simple rules, 153-167
  - terminology in reference to, 68t-69t
  - vaccination of persons who have had the disease, 165, 181t
  - vaccine handling, storage, and transport, 117-128
  - vs package insert, 59-62, 64t-65t, 153-154, 185
  - “when in doubt, vaccinate,” 165
  - working groups for, 67
- “Red Book” (*Report of the Committee on Infectious Diseases*), 71
- Refrigerator, storage of vaccines in, 119-126, 120t-123t
- Refusal of vaccination, 246-248, 246
- forms for, 247
  - modified schedules, 247
  - physician dismissal of vaccine-refusing families, 247-248
  - public harm from, 249-254
- Registries. See *Immunization Information Systems*.
- Regulations. See *Standards, principles, and regulations*.
- Religious exemptions, 112-113
- Reminder, recall, and tracking systems, 128-129
- Report of the Committee on Infectious Diseases*. See “Red Book”.
- Reportable Events Table, 97, 106t-109t
- Reporting of adverse events, 77-79, 106t-109t
- mandatory reporting, 77, 94, 101, 103t
  - to VAERS, 77-79, 101, 103t, 171t
- Respiratory disease
- adenovirus and, 303
  - vaccinations recommended, 300-301
- Respiratory syncytial virus (RSV), antibody against (palivizumab, Synagis), 19, 166, 168t
- Reverse genetics, 401
- Reverse vaccinology, 18
- Reye syndrome, 138t, 228t, 406, 408, 508, 513
- RhoGAM, 169t
- Risks and benefits of vaccines, 76, 233-244
- communicating about, 233-244, 240t-241t
  - costs of public concern, 249-254
  - human nature and, 233-237, 236
  - risks vs benefits, balancing, 237, 238t
- Rotarix (RV1), 122t, 144, 469-474, 470t-472t. See also *Rotavirus, vaccines*.
- RotaShield (RRV-TV), 237, 274, 468
- RotaTeq (RV5), 122t, 144, 274, 469-474, 470t-472t.
- See also *Rotavirus, vaccines*.
- Rotavirus, 467-476
- clinical features, 467
  - societal burden, 70
  - epidemiology and transmission, 468
  - immunization program, 237, 468-469
  - cost-effectiveness, 468-469
  - decline in rotavirus activity due to, 473-474, 473
  - pathogen, 467, 569t
  - vaccines, 469, 470t-472t
  - characteristics and specifics of, 470t-472t, 569t
  - contraindications/precautions, 469, 474
  - development cost of, 53
  - heterologous host, 16
  - immunogenicity/efficacy, 469-474, 473
  - minimum ages and intervals, 19, 159t, 166, 290
  - oral administration, 142, 144
  - reassortment and, 16
  - recommendations, 65t, 469, 475
  - infants, 469, 471t-472t, 475
  - preterm infants, 214, 475
- RRV-TV, 237, 274, 468
- RV-1 (Rotarix), 12t, 123t, 469-474, 470t-472t
- safety, 274-275, 474
- RV-5 (RotaTeq), 12t, 16, 123t, 469-474, 470t-472t
- development cost, 53
  - safety, 274-275, 474
- safety, 238t, 239t, 474
- horizontal transmission, 474
  - intussusception concerns, 237, 274-275, 468, 474
  - porcine circovirus contamination, 273
  - reportable events, 108t
  - schedule, 471t-472t
  - children, age 0-18 years, 290
  - catch-up, children, 4 months-6 years, 292
  - storage, 123t
- Routes of administration, 137-142. See also *Administration of vaccines*.
- errors in, 167
- Routine schedules. See *Schedules for immunization*.
- RSV. See *Respiratory syncytial virus (RSV)*.
- Rubella. See *Measles, Mumps, Rubella*.
- Rubeola. See *Measles*.
- Rules for vaccination, 153-167. See also *Recommendations*.
- RZV (recombinant zoster vaccine). See *Zoster*.
- Sabin, Albert, 11
- Sabin Vaccine Institute, 556t

- Safety of vaccines, 237-279, 260. See also *Adverse events*; *Vaccine Safety Net*; and *specific vaccines*.  
 communicating about, 237-244, 240t-241t  
 meaning of safety, 237  
 monitoring of safety, 76-81  
 on-time schedules, 260  
 postmarketing surveillance, 58, 76  
 safety does not mean harmless, 237  
 Vaccine Safety Net, 76-81, 78
- Salicylates. See *Aspirin*.
- Salk, Jonas, 17
- Salmonella enterica*, 499
- Salmonella typhi*, 16, 221, 499, 569t. See also *Typhoid fever*.
- Schedules for immunization, 287-302. See also *specific vaccines*.  
 adults, by age group, 298-299  
 adults, by medical indication, 300-301  
 children, age 0-18 years, 290-291  
 catch-up schedule, children age 4 months-6 years, 292-293  
 catch-up schedule, children age 7-18 years, 294-295  
 children and adolescents, routine immunizations, 290-291  
 children and adolescents, special immunizations, 296t-297t  
 flexibility within, 287  
 high-risk individuals. See *Special circumstances*  
 modified/alternative schedules, 247, 259-260  
 safety of, 260
- Schools  
 coverage surveys, 75  
 school-aged immunization platform, 302t  
 school immunization mandates, 111-113  
 school-located vaccination (SLV), 131-132
- Screening for contraindications/precautions, 134, 138t-140t, 240t-241t
- Section 317 funds, 83-86
- Self/non-self recognition, 23, 24, 25
- Serial passage, 11-16
- Seroconversion, 31  
 testing for, 171
- Serology, 167-171
- Serotype replacement, 43, 45, 490
- Sewage workers, 229t
- Sharps use and precautions, 105, 110
- Shingles. See *Zoster (herpes zoster; shingles)*.
- Shingrix (RZV; recombinant zoster vaccine), 12t, 35, 123t, 530-536, 532t-534t
- Shortages of vaccines, 86-87  
 deferral of doses and, 87
- Sickle cell disease, 192t, 199
- Side effects. See *Adverse events*.
- SIDS (sudden infant death syndrome), 271-272
- Simian immunodeficiency virus (SIV), 271
- Simian virus 40 (SV40), 270-271
- Smallpox, 477-488  
 bioterrorism potential of, 46-47, 478  
 clinical features, 477-478  
 diagnosis of, 480t-481t  
 differentiating from chickenpox, 480t-481t  
 mortality rates, 46, 477  
 correlates of protection, 38t  
 epidemiology and transmission, 478  
 immunization program, 478-479  
 ring vaccination, 478-479  
 pathogen, 477, 569t  
 cross-protection through vaccinia virus, 479  
 elimination/eradication of, 46-47, 49t, 478  
 vaccines, 124t, 479-483, 482t  
 ACAM2000, 124t, 479, 482t, 483-484  
 administration and handling, 142, 483  
 characteristics and specifics of, 482t, 569t  
 compensation for injuries from pandemic/epidemic administration, 484  
 contraindications/precautions, 153, 210, 483-484, 486t-487t  
 Dryvax, 479  
 immunogenicity/efficacy, 483, 485  
 investigational vaccines (Aventis Pasteur and Imvamune), 479-483  
 post-event vaccination, 479, 484, 485  
 pre-event vaccination, 478-479  
 recommendations, 478-479, 484-485  
 for revaccination, 485  
 safety, 483-484  
 schedule, 482t  
 storage, 124t  
 Ticovirimat (antiviral smallpox treatment), 484  
 trade name (ACAM2000), 124t, 482t  
 vaccinia immune globulin intravenous, 484
- Society of Teachers of Family Medicine, 556t
- Somatic hypermutation, 25
- Special circumstances, 183-232, 296t-297t  
 adults over 65 years of age, 215-216  
 coverage rates in special populations, 186-187, 192t-193t  
 health care personnel, 216-219  
 immune deficiency states, 187-204  
 impaired immunity, 183-185, 296t  
 B-cell (humoral) deficiencies, 191-198  
 cancer chemotherapy, 203-204  
 disease-modifying antirheumatic drugs (DMARDs), 200-201  
 hematopoietic stem cell transplantation, 204, 206t-209t  
 HIV infection, 187-191, 296t  
 solid organ transplantation, 201-204, 202  
 inborn errors of metabolism, 214-215  
 international adoptees, refugees, and immigrants, 220-221

- Special circumstances, *continued*  
 miscellaneous special situations, 227, 228t-229t  
 newborns, 186, 211  
 other predisposing conditions, 186, 204-207  
 pregnancy, postpartum, and breastfeeding, 204-211, 212t-213t, 296t  
 preterm and low birth weight infants, 214  
 travel, 221-227
- specificity of antibodies, 19, 27, 27
- Spelunkers, 229t, 460t
- Standards, principles, and regulations, 91-116. See also *Vaccine infrastructure; Vaccine practice.*  
 Bloodborne Pathogens Standard, 105-111  
 coverage goals, 91-92  
*Healthy People 2020*, 91-92  
 immunization practices, standards, 92-97  
 adult, 95-97, 98t-99t  
 child and adolescent, 92-95  
 mandates and exemptions, 111-114  
 National Childhood Vaccine Injury Act, 77, 97-101  
 National Vaccine Injury Compensation Program (VICP), 97-101  
 Occupational Safety and Health Administration (OSHA), 105-111  
 Public Readiness and Emergency Preparedness Act, 101  
 Reportable Events Table, 97, 106t-109t  
 reporting of adverse events, 77-79  
 training, 111  
 Vaccine Adverse Event Reporting System (VAERS), 77-79, 101  
 Vaccine Information Statements (VISs), 101, 102t-104t
- Standing orders, 132, 145, 369
- Steroids, 200
- Stockpiles of vaccines, 62, 87, 401, 483
- Storage of vaccines, 119-128, 120t-125t. See also *specific vaccines.*  
 emergency provisions for, 127t  
 in freezer, 119-126, 123t-124t  
 in refrigerator, 119-126, 120t-123t  
 temperature monitoring and logs, 119-126
- Streptococcus pneumoniae*, 255, 489-497, 569t. See also *Pneumococcal vaccines; Pneumonia.*  
 impaired immunity and, 186  
 optimizing immunity to, 188-190  
 serotypes and herd immunity, 43, 44, 45
- Students. See *College students.*
- Subcutaneous administration of vaccines, 141, 142
- Subunits  
 engineered, 12t, 17-18  
 purified, 12t, 17  
 recombinant, 12t, 17-18
- Sudden infant death syndrome (SIDS), 271-272
- Supply of vaccines, 86-87
- Surrogates of immunity. See *Correlates of protection.*
- Surveillance, 76. See also *Vaccine Safety Net.*  
 special surveillance efforts, 80-81  
 SV40 contamination of early polio vaccine, 270-271
- Swine flu, 80, 81
- Synagis (palivizumab), 19, 166, 168t
- Syncope, 106t-109t, 145-146
- Systems immunology, 18
- T cells, 27  
 cytotoxic (Tc cells), 25, 32-36, 34  
 activation of, 32, 34  
 deficiencies of, 184, 198  
 helper (Th-cells), 22, 24-25, 32  
 memory Th-cells, 27  
 memory T-cells, 26, 27  
 T-cell-dependent responses, 32, 35  
 T-cell-independent antigens and responses, 23, 32  
 T-cell receptor (TCR), 22, 24, 32, 34
- Table injury, 99
- Task Force on Safer Childhood Vaccines, 81
- Td (tetanus, diphtheria) vaccine, 334t-335t, 337  
 contraindication and precautions, 336-337  
 minimum ages and intervals for, 159t  
 recommendations, 337-338  
 for wound management, 340t-341t  
 schedule, 335t, 337  
 adults, by age, 298  
 adults, by medical condition/indication, 300  
 catch-up, children age 7-18 years, 294  
 trade names  
 Tenivac, 334t-335t  
 Tetanus and Diphtheria Toxoids Adsorbed, 334t-335t
- Tdap vaccines, 330t-332t. See also *Diphtheria, tetanus, and pertussis; DTaP vaccines.*  
 administration errors and remedies, 176t  
 contraindications/precautions, 336  
 Guillain-Barré syndrome, 336  
 immunogenicity/efficacy, 328  
 licensure of, 40  
 minimum ages and intervals, 159t, 290  
 recommendations, 65t, 255, 326-328, 327, 331t, 337-338  
 health care personnel, 219, 327  
 pregnancy, 205, 212t, 327, 328, 338  
 for wound management, 340t-341t  
 safety, 336  
 schedule, 331t  
 adults, by age, 298  
 adults, by medical condition/indication, 300  
 catch-up, children, age 7-18 years, 294  
 children, age 7-18 years, 290

- Tdap vaccines, *continued*  
 storage, 123t  
 trade names (Adacel, Boostrix), 330t-332t  
 vs DTaP, 164
- Temperature for vaccine storage, 119-126
- Tenivac (Td), 123t, 334t-335t. See also *Td (tetanus, diphtheria)*.
- Terminology, vi-vii, 568t-569t  
 indication, recommendation, requirement, 68t-69t  
 language and meaning, 245t
- Terrorism. See *Bioterrorism*.
- Tetanus, 323-341. See also *Diphtheria, tetanus, and pertussis*.  
 clinical features, 324  
 correlates of protection, 39t  
 epidemiology and transmission, 325  
 immune globulin (TIG), 169t, 324, 328, 340t  
 immunization program, 326  
 neonatal tetanus, 324, 325  
 pathogen, 323, 325, 568t  
 vaccines, 12t, 328, 330t-332t, 334t-335t. See also *DT; DTaP; Td; Tdap; Tetanus toxoid (TT)*.  
 characteristics and specifics of, 330t-332t, 334t-335t, 568t  
 combination vaccines, 538-539, 540t-546t  
 contraindications/precautions, 333-337  
 immunogenicity/efficacy, 328-333  
 recommendations, 326-328, 327, 337-338  
   adult. See *Tdap vaccines*.  
   children/infants. See *DTaP vaccines*.  
   for wound management, 340t-341t  
 safety, 333-337  
   reportable events, 106t  
 schedule, 331t, 334t, 337-338  
 storage, 123t  
 trade names, 330t, 334t  
   Adacel (Tdap), 330t-332t  
   Boostrix (Tdap), 330t-332t  
   Daptacel (DTaP), 330t-332t  
   Diphtheria and Tetanus Toxoids Adsorbed (DT), 334t-335t  
   Infanrix (DTaP), 330t-332t  
   Tenivac (Td), 334t-335t  
   Tetanus and Diphtheria Toxoids Adsorbed (Td), 334t-335t  
 Tetanus and Diphtheria Toxoids Adsorbed (Td), 334t-335t  
 Tetanus immune globulin (TIG), 169t, 324, 328  
 anaphylactic reaction to, 337  
 interval for live vaccines and, 169t  
 precautions, 337  
 for wound management, 340t-341t
- Tetanus toxoid (TT), 12t
- Tetanus Toxoids Adsorbed (DT, Td), 334t-335t  
 contraindications/precautions, 336-337
- Texas Children's Hospital Center for Vaccine Awareness and Research, 556t
- Th-cells (helper T lymphocytes), 22, 24-25, 32  
 differentiation of, 25  
 direct antimicrobial functions, 25  
 memory Th-cells, 26, 27
- Thimerosal, 254, 264-266. See also *specific vaccines*.
- Thrombocytopenia, 237, 275, 425
- Ticovirimat (antiviral smallpox treatment), 484
- TIG. See *Tetanus immune globulin*.
- Timeline of vaccine development, 51
- Timeliness of vaccine delivery, 73, 538
- Tofacitinib, 201
- Toll-like receptors (TLRs), 24
- Topical anesthetics, 145
- Toxins, 31, 32, 467  
 antibodies to, 19, 40  
 cholera toxin, 317, 318
- Toxoid vaccines, 12t, 17, 334t-335t, 338, 340t-341t
- Toxoids, 17
- Tracking systems, 128-129
- Transplantation  
 hematopoietic stem cell (HSCT), 204, 206t-209t  
 solid organ, 192t, 201-204, 202
- Transportation of vaccines, 126-128
- Travel, 221-227  
 disease transmission due to, 255  
 diseases related to, 226-227  
   cholera, 227, 317  
   invasive meningococcal disease, 226  
   Japanese encephalitis, 226, 415  
   measles, 221  
   rabies, 226  
   typhoid fever, 221, 226, 500  
   yellow fever, 227, 520  
 proof of vaccination, 222, 227, 525  
 travel medicine clinics, 222  
 vaccination for, 221-227  
   cholera, 227, 321  
   hepatitis A (or IGIM), 222-223, 350, 355  
   hepatitis B, 222-223, 370  
   influenza, 221  
   Japanese encephalitis, 415  
   mandatory vaccines, 227  
   measles, 221  
   meningococcal vaccine (Saudi Arabia/Hajj), 227  
   *N meningitidis*, 195, 226, 443  
   polio, 223-226, 449  
   rabies, 226, 460t  
   routine vaccines, being up-to-date, 222  
   typhoid fever, 505



- Travel, *continued*  
 Web sites on, 227  
 yellow fever, 227, 524-525
- Trumenba (MenB-FHbp), 175t, 435, 436t-439t  
 immunogenicity, 441  
 minimum ages and intervals, 158t  
 recommendations, 64t, 433, 435  
 storage, 122t
- Tsar/Tsarina (for immunization), 117, 118t, 134
- TT. See *Tetanus toxoid (TT)*.
- Tuberculin skin test (TST), 425, 484, 513, 524
- Tuberculosis, 16
- TViPSV. See *Typhim Vi*.
- Twinrix (HepA-HepB), 121t, 538, 548t-551t
- Ty21a. See *Vivotif*.
- Typhim Vi (TViPSV), 123t, 501-505, 502t-503t
- Typhoid fever, 499-506  
 clinical features, 499-500  
 epidemiology and transmission, 500  
 immunization program, 500  
 pathogen, 499, 569t  
 vaccines, 501, 502t-503t, 569t  
 contraindications/precautions, 191, 504  
 immunogenicity/efficacy, 501  
 recommendations, 500, 505  
   for travel, 226, 505  
 safety, 504  
 schedule, 503t  
 storage, 123t  
 TViPSV (Typhim Vi), 123t, 501-505, 502t-503t  
 Ty21a (Vivotif), 16, 501-505, 502t-503t
- Universal precautions, 110
- Vaccinate Your Family, 556t
- Vaccination. See also *Immunization; Vaccinology*.  
 basic concepts, 11-52  
 as civic duty, 247  
 coverage goals, 91-92  
 cytotoxic T cells, implications for, 32-35  
 defined, 11  
 general recommendations, 153-181  
 germinal center reaction, implications for, 26-32  
 goals, 46-48  
 public health impact of, 46-50, 49t, 52t  
 sources of information on, 240-241, 242  
 triumphs of, 49t
- Vaccination programs. See *specific diseases*.
- Vaccine(s). See also *Immunization; specific vaccines*.  
 abbreviations, 559t-560t  
 basic immunology of, 19-36  
 classification of, 12t-13t  
 concerns about, 233-285  
 correlates of protection, 36-40, 38t-39t  
 costs/cost-benefit analyses. See *Costs*.  
 delivery of. See *Delivery of vaccines*.  
 development of. See *Vaccine development and licensure*.  
 documentation of vaccinations received, 128  
 effectiveness, vs efficacy, 36, 58  
 funding for. See *Financing*.  
 how they work, 19-36  
 impact of, 48-50, 49t, 52t  
 inactivated, 12t, 14t, 17-18  
 interchangeability of vaccines from different manufacturers, 164  
 licensure of. See *Vaccine development and licensure*.  
 live vaccines, 11-16, 12t-13t, 21  
 live vs inactivated vaccines, 14t-15t, 35  
 National Vaccine Plan, 71, 97  
 necessity of, 254-255  
 nomenclature, vi-vii, 568t-569t  
 number of, and timeline of development, 50, 51  
 prices of. See *Costs*.  
 recommendations regarding. See *Recommendations*.  
 resources on, 554t-558t  
 schedules for. See *Schedules for immunization*.  
 stockpiles of, 62, 87, 401, 483  
 supply/shortages, 86-87  
 timeline of development for specific diseases, 51  
 valency, vii  
 virus stocks, destruction of, 46-47
- Vaccine acceptance, hesitancy, and confidence, 233, 234t
- Vaccine Adverse Event Reporting System (VAERS), 77-79, 101  
 limitations of, 78  
 mandatory reporting to, 77, 94, 101, 103t
- Vaccine confidence, 233, 234t, 244
- Vaccine development and licensure, 53-62, 54  
 agencies involved with, 54, 66, 78  
 animal models, 53  
 Biologics License Application (BLA), 58-59  
 “breakthrough therapy” category, 59  
 clinical trials, 55-58, 56  
 costs of, 53  
 emergency preparedness, 62  
 FDA and, 53-55, 54  
 financial risk involved, 53  
 financing for, 81-86  
 noninferiority standard, 56, 538

- Vaccine development and licensure, *continued*  
 package insert (PI), 59-62  
 postmarketing activities, 58, 76  
 prelicensure trials, 55-58, 56  
 steps in, 53-59, 54, 56  
 timeline for specific vaccines, 51  
 VRBPAC and, 59, 66
- Vaccine failure, 31, 58, 60t-61t  
 causes of, 60t-61t
- Vaccine immunology, 19-36. See also *Immune response*.
- Vaccine Information Statements (VISs), 101, 102t-104t, 239
- Vaccine infrastructure in the U.S., 53-90, 54  
 Defense Medical Surveillance System, 80  
 disease surveillance, 76  
 emergency preparedness, 62, 101, 145-146  
 financing, 81-86  
 governmental agencies, 54, 66, 554t  
 monitoring delivery, 73-75  
 monitoring safety, 76-81  
 policy and recommendations, 62-72  
 supply, 86-87  
 vaccine development and licensure, 53-62, 54, 78  
 Vaccine Safety Net, 76-81, 78
- Vaccine Injury Compensation Program (VICP), 66, 97-101.  
 See also *Vaccine Adverse Event Reporting System (VAERS)*.  
 children in utero covered by, 211  
 compensation under, 100  
 proof of causation, 99  
 Reportable Events Table, 106t-109t  
 Table injury, 99  
 vaccines covered, 100, 103t (footnote e)
- Vaccine Injury Table (VIT), 97, 106t-109t  
 Table injury, 99
- Vaccine policy and recommendations, 62-72. See also *Recommendations*.  
 agencies involved with, 66  
 terms used in reference to, 68t-69t
- Vaccine practice, 117-152. See also *Administration of vaccines*.  
 administration of vaccines, 135-150  
 coding, billing, and costs, 146-150  
 delivery of vaccines, improving, 128-134  
 emergencies, 127t, 145-146  
 general guidelines, 117-128  
 handling, storage, and transport, 117-128  
 inventory, 117-118  
 signs, 117, 119, 126  
 storage, 119-128, 120t-125t  
 transport, 126-128  
 Immunization Tsar/Tsarina, 117, 118t, 134  
 screening for contraindications, 134, 138t-140t  
 standards for, 92-97
- Vaccine-preventable diseases, 51, 67. See also *Public health*.  
 annual deaths from, 95, 392, 393-394, 394  
 costs of, 95  
 immunization goals, 91-92  
 necessity of vaccination for, 254-255  
 resurgence of, 48, 249-254, 326, 421-424  
 surveillance, 76  
 timeline of specific vaccine development, 51
- Vaccine purchasing group (VPG), 147
- Vaccine recommendations. See *Recommendations*.
- Vaccine refusal, 246-248, 246
- Vaccine Safety DataLink (VSD), 79, 145, 205
- Vaccine Safety Net, 76-81, 78  
 ad-hoc committees and task forces, 81  
 Brighton Collaboration, 80  
 Clinical Immunization Safety Assessment (CISA) Network,  
 79-80, 555t  
 Defense Medical Surveillance System, 80  
 IOM Consensus Report, 81  
 Post-licensure Rapid Immunization Safety Monitoring (PRISM), 79  
 special surveillance efforts, 80-81  
 Vaccine Adverse Event Reporting System (VAERS), 77-79, 101  
 Vaccine Safety DataLink, 79
- Vaccines and Related Biological Products Advisory Committee  
 (VRBPAC), 59, 66
- Vaccines for Children (VFC) Program, 63, 82-83, 118  
 common questions about, 84t-85t
- Vaccines.gov, 556t
- Vaccinia immune globulin, 484
- Vaccinia virus, 479. See also *Smallpox*.
- Vaccinology, 11-52. See also *Immunization*.  
 basic vaccine immunology, 19-36  
 classical vs reverse, 18  
 correlates of protection, 36-40, 38t-39t  
 genetics of vaccine responses/adverse events, 43-46  
 herd immunity, 40-43, 41  
 immunization, 11-19  
 public health and vaccines, 46-50, 49t  
 systems immunology, 18
- Vaccinomics, 46
- VAERS. See *Vaccine Adverse Event Reporting System*.
- Value of Vaccination, 556t
- Vaqa (HepA), 120t, 351, 352t-354t
- Varicella, 507-517  
 chickenpox, 35, 164, 165, 255, 480t, 507  
 clinical features, 507-508, 511  
 breakthrough/vaccine-modified varicella, 507-508  
 congenital varicella syndrome, 508  
 diagnosis, 480t-481t  
 differentiating from smallpox, 480t-481t

Varicella, *continued*

progressive and hemorrhagic varicella, 508  
 societal burden of, 70, 509  
 correlates of protection, 39t  
   evidence of immunity, 515t  
 epidemiology and transmission, 508  
 herpes zoster (shingles) and. See *Zoster*.  
 immune globulin (VariZIG), 169t, 509, 513, 514-516  
 immunization program, 509, 511  
   cost effectiveness of, 509  
   one-dose program, 48, 509  
   two-dose program, 509  
 pathogen (varicella-zoster virus, VZV), 507, 569t  
   attenuation of, 11-16  
   latency and, 507, 512, 527  
   reactivation of latent, 35, 507, 508, 512, 527, 528  
 vaccines (VAR), 509-514, 510t-511t. See also *MMRV*; *Zoster*  
   administration errors and remedies, 176t  
   contraindications/precautions, 512-513  
   evidence of immunity, 515t  
   immunogenicity/efficacy, 509-512  
   interval for receipt of antibody-containing products,  
     165-166, 168t-170t  
   minimum ages and intervals, 153, 159t, 290  
   primary vaccine failure, 509  
   recommendations, 509, 514-516  
     considerations in, 70  
     health care personnel, 219, 509  
     HIV-infected children, 187-191  
     MMR plus VAR, preferred over MMRV, 420, 538, 539  
     pregnant women and, 514-516  
   safety, 512-513  
     reportable events, 108t  
   schedule, 510t, 514  
     adults, by age, 298  
     adults, by medical condition, 300  
     children, age 0-18 years, 290  
     catch-up, children age 4 months-6 years, 293  
     catch-up, children age 7-18 years, 294  
   serial passage, 11-16  
   storage and transport, 124t, 126  
   trade name (Varivax), 124t, 510t-511t  
   vs zoster vaccines (ZVL), 35  
 VariZIG (varicella zoster immune globulin), 169t, 509,  
 513, 514-516  
   waning immunity and, 508, 527  
 Varicella-zoster immune globulin. See *VariZIG*.  
 Varicella-zoster virus (VZV), reactivation of latent, 35, 507, 508,  
 512, 527, 528. See also *Zoster* (*herpes zoster*; *shingles*).

Variola, 477-478, 569t. See also *Smallpox*.

last remaining stocks of, 46-47, 478  
 terrorism potential of, 46-47, 478  
 variola major, minor, and sine eruptione, 478-479  
 Varivax (varicella vaccine), 124t, 509-514, 510t-511t. See also  
*Varicella*, *vaccines*.

VariZIG (varicella zoster immune globulin), 18, 169t, 509,  
 514-516. See also *Varicella*.  
 for health care personnel, 219  
 IgA deficiency and, 513  
 interval for live vaccines and, 169t  
 for pregnant women, 211, 514-516  
 safety, 513

Vaxchora (cholera vaccine), 123t, 227, 319, 320t

Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t

VFC. See *Vaccines for Children (VFC) Program*.

*Vibrio cholerae*, 16, 317, 568t

VICP. See *Vaccine Injury Compensation Program*.

Viral infections, 35

Viral interference, 537

Viruses, vs bacteria, 32-35

Vivotif (Ty21a), 16, 123t, 501-505, 502t-503t

Voices for Vaccines, 556t

VRBPAC (Vaccines and Related Biological Products

Advisory Committee), 59, 66

VZV (varicella-zoster virus), 507. See also *Varicella*

Waning immunity, 48, 255, 329, 509, 527

Warning labels, 110

Whole agent vaccines, 12t, 17

Whooping cough. See *Pertussis*.

Woolsorter's disease, 309

World Health Organization (WHO), 554t

X-linked agammaglobulinemia (XLA), 184

Yellow fever, 519-526

clinical features, 519

epidemiology and transmission, 520

immunization program, 520

International Certificate of Vaccination or Prophylaxis, 227, 525

pathogen, 519, 569t

vaccine for (YFV), 12t, 123t, 521-525, 522t-523t

adverse events, serious, 521-523

approved sites for administration, 227, 525

contraindications/precautions, 211, 523-524

immunogenicity/efficacy, 521

recommendations, 154, 524-525

for pregnant women, 177, 212t, 524, 525

travel, 227, 524-525

Yellow fever, *continued*

safety, 273, 521-524

vaccine-associated neurotropic disease, 523, 525

vaccine-associated viscerotropic disease, 521-523

schedule, 522t

storage, 123t

YF-Vax (yellow fever vaccine), 12t, 123t, 521-525, 522t-523t

Zostavax (ZVL, zoster vaccine live), 65t, 530-536, 532t-534t

storage, 124t

Zoster (herpes zoster; shingles), 527-536. See also *Varicella*.

clinical features, 527-528

age and, 528

zoster sine herpete, 528

correlates of protection, 39t

epidemiology and transmission, 528-529

reactivation of latent VZV, 35, 507, 508, 512, 527, 528

risk factors and incidence, 528-529

varicella vaccination, protection provided by, 529

herpes zoster (shingles), 35, 256, 507-508, 527

immunization program, 529-530

cost-effectiveness of, 529-530

pathogen, 527, 569t

postherpetic neuralgia (PHN) and, 256, 527, 528

vaccines for (ZVL, RZV), 12t, 530-536, 532t-534t

administration errors and remedies, 175t, 176t

contraindications/precautions, 531-535

immunogenicity/efficacy, 530-531

live-attenuated (ZVL), 12t, 35, 65t, 530-536, 532t-534t

minimum ages and intervals, 159t, 166

recombinant (RZV), 12t, 35, 123t, 530-536, 532t-534t

recommendations, 65t, 216, 530, 535-536

safety, 531-535

schedule, 533t

adults, by age, 298, 535

adults, by medical condition/indication, 300

storage, 123t, 124t

trade names (Zostavax; Shingrix), 532t

vs varicella vaccine (VAR), 35

varicella exposure and, 529

ZVL (zoster vaccine live). See under Zoster.